

**A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis**

**Study Code: GWSP20105**

**EudraCT Number: 2020-003271-18**

**CLINICAL PROTOCOL**

**GW Pharma Ltd  
Sovereign House  
Vision Park  
Chivers Way  
Histon  
Cambridge CB24 9BZ  
United Kingdom**

**Tel: +44 (0) 1223 266 800  
Fax: +44 (0) 1223 235 667**

**Confidentiality Statement**

This document contains confidential information of GW Pharma Ltd (GW) that must not be disclosed to anyone other than the recipient trial staff and members of the institutional review board or independent ethics committee. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of GW.

### **Investigator Agreement**

I have read the attached clinical protocol entitled "A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis," dated 22 July 2020 and agree to abide by all provisions set forth therein.

I agree to comply with applicable regulatory requirement(s); the US Food and Drug Administration (FDA) regulations relating to Good Clinical Practice (GCP) and clinical trials, the European Union (EU) Clinical Trials Directive (2001/20/EC), the EU GCP Directive (2005/28/EC) and subsequent applicable regulatory/statutory instruments, or the International Council for Harmonisation Tripartite Guidelines for GCP where the EU Clinical Trials and GCP Directives do not apply, and to complete Form FDA 1572, if required. I accept responsibility for the overall medical care of patients during the trial and for all trial-related medical decisions.

I am not aware that any conflicts of interest, financial or otherwise, exist for myself, my spouse (or legal partner) and dependent children and agree to confirm this in writing if required and update as necessary.

I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of GW.

Trial site No: \_\_\_\_\_

Print name: \_\_\_\_\_

Principal investigator

Date: \_\_\_\_\_

(DD Month YYYY)

Signature: \_\_\_\_\_

### GW Authorization


Print name: \_\_\_\_\_

\_\_\_\_\_ Clinical Sciences

Date: 29-Jul-2020 | 14:30 PDT

(DD Month YYYY)

Signature: \_\_\_\_\_



## **1 PROTOCOL SYNOPSIS**

Trial Title	A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
Clinical Trial Type	Phase 3
Indication	Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
Primary Objective	To evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6; LLMT-6) in patients with MS
Secondary Objectives	<ul style="list-style-type: none"><li>• To evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone 4; LLMT-4) in patients with MS</li><li>• To evaluate the safety and tolerability of nabiximols after administration of multiple doses</li><li>• To evaluate the pharmacokinetic (PK) profile of nabiximols after administration of multiple doses</li></ul>
Exploratory Objectives	<ul style="list-style-type: none"><li>• To evaluate the effect of nabiximols after administration of multiple doses on walking using the Timed 25-Foot Walk (T25FW) test</li><li>• To evaluate the effect of nabiximols after administration of multiple doses on the following patient-reported outcomes:<ul style="list-style-type: none"><li>– The 11-point Numerical Rating Scale (NRS) spasticity score</li><li>– Daily spasm count</li><li>– The MS Spasticity Scale (MSSS-88) total and subdomain scores</li></ul></li></ul>
Trial Design	<p>This multicenter, randomized, double-blind, placebo-controlled, 2-treatment, 2-period, Phase 3 crossover trial is being conducted to evaluate the effect of multiple doses of nabiximols on clinical measures in the symptomatic treatment of patients with MS.</p> <p>Patients with spasticity associated with MS will participate in a screening period of up to 28 days; no changes in the dosing regimen of the patients' current MS antispasticity medications, if any, will be made during this period.</p> <p>As part of the baseline period of each treatment period, patients will keep an electronic diary to record 11-point NRS spasticity score, spasm count, and use of antispasticity medications once daily, around the same time each day, preferably in the evening before retiring to sleep, for at least 7 days prior to Visits 2 and 6. At Visit 2, in the morning of Day 1, eligible patients will be randomly assigned in a 1:1 ratio to 1 of 2 treatment sequences, each composed of 2 treatment</p>

	<p>periods, with administration of multiple doses of nabiximols or placebo.</p> <p>Patients randomized will complete 2 treatment periods with administration of investigational medicinal product (IMP) for 21 days per treatment period. Each treatment period will consist of a dose-titration phase of approximately 14 days, followed by a maintenance-dose phase of approximately 7 days, where the individually determined optimized dose level remains unchanged for the remainder of each treatment period after titration. Doses greater than 1 spray/day will be divided into a morning dose and an evening dose.</p> <p>Throughout both treatment periods, patients will initiate IMP treatment as a single spray in the clinic in the morning of Visits 2 (Day 1) and 6 (Day 31) of each treatment period. Patients will gradually titrate their daily dose by 1 to 2 additional sprays/day to an optimized dose or to a maximum of 12 sprays/day over the first approximately 14 days of treatment with an approximately 15-minute interval between sprays. Patients should complete titration within approximately 14 days of their first dose of IMP in each treatment period and should continue at the same dose level achieved at the end of the titration phase (i.e., their daily optimized dose) <math>\pm</math>1 spray divided into a morning dose and an evening dose for the remainder of the treatment period. Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays. Patients will be advised to administer IMP at approximately the same time each day in a consistent manner in relation to food consumption. Morning and evening doses should be administered around the same time within 30 minutes after starting a snack or meal.</p> <p>On the days of scheduled Modified Ashworth Scale (MAS) assessments other than Visit 1 (i.e., Visits 2, 5, 6, and 9), patients will attend the trial site without having administered any IMP in the morning. On the day of MAS assessment, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before the administration of IMP. Administration of the morning dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) will occur at the trial site under the supervision of site staff; MAS assessments will occur at scheduled time points before (Visits 2 and 6 [predose]) and after (Visits 2, 5, 6, and 9 [3 hours <math>\pm</math>15 minutes postdose]) IMP administration.</p> <p>A washout period of at least 7 days will separate the 2 treatment periods. During the washout period, patients will continue to take their current MS antispasticity medications, if any, without any changes in dosing regimen.</p> <p>Patients who complete the 2 treatment periods will complete an End of Treatment Visit (Visit 9). Patients who discontinue IMP early will be encouraged to remain in the study for the duration of the treatment</p>
--	--

	<p>period in which they discontinue IMP and will complete an End of Treatment Visit (Visit 9) at the end of that period. A Safety Follow-up Visit (Visit 10) will occur 7 (+ 3) days after the last dose of IMP or after the End-of-Treatment visit (Visit 9), whichever is later, for all patients.</p>
Primary Endpoint	<p>Change in Lower Limb Muscle Tone-6 (LLMT-6; defined as the average of the 6 individual MAS transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body) from Day 1 predose to Day 21 and from Day 31 predose to Day 51</p> <p>The MAS scores are transformed using the following algorithm: MAS untransformed [to MAS transformed] scores; 0[0], 1[1], 1+[2], 2[3], 3[4], and 4[5].</p>
Secondary Endpoints	<p>Efficacy:</p> <ul style="list-style-type: none"><li>Change in Lower Limb Muscle Tone-4 (LLMT-4; defined as the average of the 4 individual MAS transformed scores of knee flexors and knee extensors on both sides of the body) from Day 1 predose to Day 21 and from Day 31 predose to Day 51</li></ul> <p>Safety:</p> <ul style="list-style-type: none"><li>Frequency of treatment-emergent adverse events (TEAEs)</li><li>Change from baseline to each assessment time point by treatment period for the following:<ul style="list-style-type: none"><li>Clinical laboratory parameters</li><li>Vital signs</li><li>Physical examination procedures</li><li>12-lead electrocardiograms (ECGs)</li></ul></li><li>Columbia-Suicide Severity Rating Scale (C-SSRS) at screening, and at each subsequent time point with reference to the last assessment (since last visit)</li></ul> <p>Pharmacokinetics:</p> <ul style="list-style-type: none"><li>Plasma concentrations for <math>\Delta^9</math>-tetrahydrocannabinol (THC) and its relevant metabolites (11-hydroxy-<math>\Delta^9</math>-tetrahydrocannabinol and 11-carboxy-<math>\Delta^9</math>-tetrahydrocannabinol) and cannabidiol (CBD) and its relevant metabolites (7-hydroxy-cannabidiol and 7-carboxy-cannabidiol) at distinct time points during each treatment period (Visits 2, 4, 5, 6, 8, and 9)</li></ul>

Exploratory Endpoints	<p>Efficacy:</p> <ul style="list-style-type: none"><li>• Change in Timed 25-Foot Walk (T25FW) test from Day 1 predose to Day 21 and from Day 31 predose to Day 51</li><li>• Average 11-point NRS spasticity score over the last 7 days of each double-blind treatment period</li><li>• Average daily spasm count over the last 7 days of each double-blind treatment period</li><li>• Total and subdomain scores of the MSSS-88 at the end of the maintenance-dose phase of each double-blind treatment period</li></ul>
Sample Size	<p>The trial will consist of 2 treatment sequences. A total of approximately 190 patients will be required. Approximately 95 patients will be randomly assigned to each treatment sequence to ensure that at least 170 patients in total complete the 2 treatment periods. This assumes a true difference of -0.18, and standard deviation (SD) for paired differences of 0.71 for 90% power.</p> <p>If more than 20 patients withdraw from the study, additional patients will be enrolled to have at least 170 completers.</p> <p>Additional data, collected outside of this trial, may become available during study conduct. Based on such data, the sample size may be recalculated using a blinded reassessment and updated assumptions of treatment effect and variability, while maintaining study blind and type 1 error.</p>
Summary of Patient Eligibility Criteria	<p><b>Inclusion Criteria</b></p> <p><i>Screening (Visit 1)</i></p> <p>For inclusion in the trial, patients must fulfill ALL of the following criteria:</p> <ul style="list-style-type: none"><li>• Male or female, aged 18 years or above.</li><li>• Willing and able to give informed consent for participation in the trial.</li><li>• Willing and able (in the investigator's opinion) to comply with all trial requirements.</li><li>• Has had a diagnosis with any disease subtype of MS, by revised 2017 McDonald criteria, for at least 12 months prior to Visit 1 and is expected to remain stable for the duration of the trial.</li><li>• Has an MAS untransformed score of at least 2 in 2 or more of 6 muscle groups (right knee flexors, left knee flexors, right knee extensors, left knee extensors, right plantar flexors, or left plantar flexors) at Visit 1.</li><li>• If currently receiving approved anti-spasticity therapy, it must be with a stable dosing regimen for at least 30 days prior to Visit 1. The patient must be willing to maintain the same antispasticity medication and not plan to initiate a new course of physiotherapy for the duration of the trial.</li></ul>

- If currently receiving an approved MS disease-modifying therapy, it must be at a stable dose for at least 3 months prior to Visit 1 and be expected to remain stable for the duration of the trial.
- If currently receiving dalfampridine or fampridine, it must be at a stable dose for at least 3 months prior to Visit 1 and is expected to remain stable for the duration of the trial.
- Willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
- Willing to allow his or her primary care practitioner (if he or she has one) and/or treating neurologist (if he or she has one) to be notified of participation in the trial, if the primary care practitioner/treating neurologist is different from the investigator.

*Additional Inclusion Criteria at Randomization (Visit 2)*

Patients are eligible for randomization in the trial if, in addition to continuing to meet the Screening (Visit 1) inclusion criteria, they also meet the following criterion prior to Visit 2 (Day 1):

- Completed at least 5 of 7 days of their electronic diary reporting during the 7 days immediately preceding Visit 2 (Day 1).

**Exclusion Criteria**

The patient may not enter the trial if ANY of the following apply:

- Has taken nabiximols, cannabis, or a cannabis-derived product for medicinal or recreational purposes in the 30 days prior to Visit 1 or unable to abstain for the duration of the study.
- Did not tolerate or did not respond adequately to treatment with nabiximols or another cannabis-based medication if exposed at any time before the 30-day period prior to Visit 1.
- Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the patient's level of spasticity.
- Medical history suggests that relapse/remission is likely to occur during the trial, which, in the opinion of the investigator, is expected to influence the patient's spasticity.
- Has had a relapse of MS within the 60 days prior to Visit 1.
- Currently using botulinum toxin injection for the relief of spasticity (within 6 months of Visit 1) or is unwilling to abstain for the duration of the trial.
- Currently taking antipsychotic medication.
- Currently taking benzodiazepines unless doses and dosing regimen have been stable for at least 30 days prior to Visit 1.

	<ul style="list-style-type: none"><li>• Clinically suspected to have a contracture in one of the muscle groups of the lower limbs, preventing assessment with the MAS.</li><li>• Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP.</li><li>• Has experienced myocardial infarction or clinically significant cardiac dysfunction within the 12 months prior to Visit 1 or has a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction.</li><li>• Has a diastolic blood pressure of &lt; 50 mmHg or &gt; 105 mmHg or systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg (when measured in a sitting position at rest for 5 minutes) or a postural drop in the systolic blood pressure of &gt; 20 mmHg at Visit 1 or Visit 2. All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.</li><li>• Has clinically significant impaired renal function at Visit 1, as evidenced by an estimated creatinine clearance lower than 50 mL/min. All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.</li><li>• Has moderately impaired hepatic function at Visit 1, defined as serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 × upper limit of normal (ULN). All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.</li><li>• Male and fertile (i.e., after puberty unless permanently sterile by bilateral orchectomy) unless willing to ensure that he uses male contraception (condom or vasectomy) or remains sexually abstinent during the trial and for 3 months thereafter.</li><li>• Female and of childbearing potential (i.e., following menarche and until becoming postmenopausal for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that she uses a highly effective method of birth control (e.g., intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence) during the trial and for 3 months thereafter. Patients using combined hormonal methods or a progestogen-only pill or injection or implant should use an additional barrier method such as a male condom or diaphragm during the trial and for 3 months thereafter.</li><li>• Female and pregnant (positive pregnancy test at Visit 1 or Visit 2), lactating, or planning pregnancy during the course of the trial or within 3 months thereafter.</li></ul>
--	---

	<ul style="list-style-type: none"><li>• Has received an IMP within the 30 days prior to Visit 1.</li><li>• Has any other clinically significant disease or disorder (including seizure disorder) that, in the opinion of the investigator, may put the patient, other patients, or site staff at risk because of participation in the trial, influence the interpretation of trial results, or may affect the patient's ability to take part in the trial.</li><li>• Has any abnormalities identified following a physical examination, clinical laboratory, serology, or other applicable screening procedures that, in the opinion of the investigator, would jeopardize the safety of the patient or the conduct of the study if he or she took part in the trial.</li><li>• Has any history of suicidal behavior in the 5 years prior to Visit 1 or a score of 3, 4, or 5 on the C-SSRS in the month prior to Visit 1.</li><li>• Has donated blood during the 3 months prior to Visit 1 and is unwilling to abstain from donation of blood during the trial.</li><li>• Has been previously randomized into this trial.</li><li>• Has any known or suspected history of alcohol or substance abuse (including opiate abuse) or dependence within 1 year prior to Visit 1.</li><li>• Currently using an illicit drug or current nonprescribed use of any prescription drug.</li><li>• Has a history of psychiatric or neurologic disorder that, in the opinion of the investigator, may interfere with trial participation, data interpretation, or conduct of trial procedures.</li><li>• Has a history of severe psychiatric disorder that may be exacerbated by the use of a cannabinoid-containing product.</li><li>• Has any planned clinical interventions or intends to change any or all medications that may have an effect on spasticity or MS during the trial.</li><li>• Currently taking drugs that are solely metabolized by UGT1A9 and UGT2B7.</li><li>• Currently taking strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort).</li></ul>
Criteria for Withdrawal	<p>The patient <u>must</u> be withdrawn from the trial if any of the following apply:</p> <ul style="list-style-type: none"><li>• Administrative decision by the investigator, GW Pharma Ltd, or regulatory authority</li><li>• Withdrawal of patient consent</li><li>• Lost to follow-up</li></ul>

	<p>The patient <u>must</u> cease IMP and should remain in the trial if any of the following apply:</p> <ul style="list-style-type: none"><li>• Pregnancy</li><li>• Protocol deviation that is considered to potentially compromise the safety of the patient</li><li>• Suicidal behavior or ideation of type 4 or 5 during the treatment period, as evaluated with the C-SSRS</li><li>• ALT or AST <math>&gt; 3 \times</math> ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (<math>&gt; 5\%</math>)</li><li>• ALT or AST <math>&gt; 5 \times</math> ULN</li><li>• ALT or AST <math>&gt; 3 \times</math> ULN <b>and</b> (total bilirubin [TBL] <math>&gt; 2 \times</math> ULN <b>or</b> international normalized ratio [INR] <math>&gt; 1.5</math>)</li></ul> <p>The patient <u>may</u> be required to cease IMP at the discretion of the investigator and should remain in the trial for any of the following reasons:</p> <ul style="list-style-type: none"><li>• Did not meet eligibility criteria</li><li>• Patient noncompliance</li><li>• AE (including clinically significant laboratory result) that, in the opinion of the investigator, would compromise the continued safe participation of the patient in the trial</li><li>• Any evidence of drug abuse or diversion</li><li>• Disease progression (defined as a relapse of MS requiring a change in treatment)</li></ul>
Investigational Medicinal Product: Formulation, Mode of Administration, Dose and Regimen	<p>Nabiximols oromucosal spray is a mixture of THC and CBD extracts derived from <i>Cannabis sativa</i> L. Each of the botanical extracts contains a cannabinoid as the major constituent (i.e., THC or CBD) and minor constituents including other cannabinoid and noncannabinoid plant components, including alpha- and trans-caryophyllenes, other terpenes, sterols, and triglycerides.</p> <p>Nabiximols is presented as an oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL) as well as other non-cannabinoid plant components, dissolved in ethanol:propylene glycol (50% v/v) excipients with peppermint oil (0.05% v/v) flavoring. Each spray delivers 100 <math>\mu</math>L of nabiximols.</p> <p>Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 <math>\mu</math>L containing no active ingredients.</p> <p>Treatment will be initiated in the clinic in the morning of Visits 2 (Day 1) and 6 (Day 31) of each treatment period. The total daily dose should be administered as a morning dose and an evening dose, which may be composed of a different number of sprays during titration. Patients will be advised to administer IMP at approximately the same</p>

	<p>time each day in a consistent manner in relation to food consumption. Morning and evening doses should be administered around the same time within 30 minutes after starting a snack or meal. Patients will gradually titrate their daily dose to the maximally acceptable dose, balancing efficacy and tolerability, or to a maximum number of 12 sprays/day. During the titration phase, there should be an approximately 15-minute interval between sprays.</p> <p>Patients should complete titration within approximately 14 days of their first dose of IMP in each treatment period and should continue at the same dose level achieved at the end of titration phase (i.e., their daily optimized dose) <math>\pm</math> 1 spray/day divided into a morning dose and an evening dose for the remainder of the treatment period.</p> <p>Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays.</p> <p>Throughout each treatment period, patients will be advised to administer IMP at approximately the same time each day in a consistent manner in relation to food consumption.</p>
Control Arm	All patients enrolled in the trial will receive both nabiximols and placebo during the 2-way crossover treatment period.
Procedures	<p>Assessments/procedures at the trial site include the following:</p> <ul style="list-style-type: none"><li>• Informed consent, demographics, previous cannabis use, medical history, electronic diary training, and blood THC test (Visit 1)</li><li>• Eligibility check and urine drug screen (including THC) (Visits 1 and 2 [predose])</li><li>• Randomization and IMP dosing training (Visit 2 [predose])</li><li>• Concomitant medications review, AE review, and vital signs (when at the trial site) measurement (Visits 1 through 10)</li><li>• Physical examination (including height measurement at Visit 1 only), 12-lead ECG, and clinical laboratory blood sampling (hematology and biochemistry) (Visits 1, 5, and 9)</li><li>• Examination of oral mucosa (Visits 1, 2 [predose], 4, 5, 6 [predose], 8, 9, and 10)</li><li>• Body weight measurement (Visits 1, 2 [predose], 6 [predose], and 10)</li><li>• Dipstick urinalysis and serum pregnancy test (if appropriate) (Visits 1 and 10)</li><li>• Urine pregnancy test (if appropriate) (Visits 2 and 6 [predose])</li><li>• PK blood sampling (IMP) at distinct time points (Visits 2, 4, 5, 6, 8, and 9)</li></ul>

	<ul style="list-style-type: none"><li>• MAS assessment (Visits 1, 2 [predose and at 3 hours <math>\pm</math>15 minutes postdose], 5 [3 hours <math>\pm</math>15 minutes after the first spray of the morning dose], 6 [predose and at 3 hours <math>\pm</math>15 minutes postdose], and 9 [3 hours <math>\pm</math>15 minutes after the first spray of the morning dose])</li><li>• MSSS-88 assessment (Visits 5 and 9)</li><li>• T25FW test (Visits 2 [predose], 5, 6 [predose], and 9)</li><li>• C-SSRS assessment (Visits 1, 2 [predose], 4, 5, 6 [predose], 8, 9, and 10)</li><li>• IMP dosing at the investigational site (Visits 2, 5, 6, and 9)</li><li>• IMP dispensing (Visits 2, 4, 6, and 8)</li><li>• IMP collection and compliance review (Visits 4, 5, 8, and 9)</li></ul> <p>Additional procedures to screen for the presence of or immunity against infectious diseases may be conducted according to local guidance and policy. In cases where patients are not able to attend study visits due to the presence of an infectious disease or other transmissible condition, the investigator will discuss with the Sponsor potential mitigation approaches.</p>
Statistical Considerations	The Lower Limb Muscle Tone-6 (LLMT-6) will be derived as the average of individual MAS transformed scores (of left knee flexors, right knee flexors, left knee extensors, right knee extensors, left plantar flexors, and right plantar flexors) for each patient. The change from baseline in LLMT-6 in treatment period 1 for each patient will be derived as LLMT-6 at Day 21 minus LLMT-6 at Day 1 predose and the change from baseline in LLMT-6 in treatment period 2 for each patient will be derived as LLMT-6 at Day 51 minus LLMT-6 at Day 31 predose. The primary estimand involves the mean treatment


	<p>difference between the mean change from baseline in LLMT-6 while on nabiximols and the mean change from baseline in LLMT-6 while on placebo. The changes from baseline in LLMT-6 will be analyzed using a linear mixed effects model for crossover data. The model will include a period level baseline covariate and treatment, period, and treatment sequence as fixed effects and patient nested within treatment sequence as a random effect. Secondary endpoints and exploratory endpoints will be analyzed based on the statistical analysis plan.</p> <p>Statistical hypothesis testing will be 2-tailed and carried out at the 5% level of significance. Testing will be performed on the primary endpoint, secondary endpoints, and exploratory endpoints as appropriate.</p> <p>To control for Type 1 error, the primary efficacy endpoint and the secondary efficacy endpoint will be tested hierarchically, starting with the primary efficacy endpoint and followed by the secondary efficacy endpoint. No adjustments for multiplicity will be made for the other secondary or exploratory endpoints.</p> <p>Safety data will be summarized using appropriate statistical methods. Additional data, collected outside of this trial, may become available during study conduct. Based on such data, the statistical approach for this study may be amended based on updated assumptions of treatment effect and variability, while maintaining study blind and type 1 error.</p>
Sponsor	GW Pharma Ltd Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ United Kingdom

**Figure 1-1**  
Trial Design and Treatment Schematic

**Treatment Period 1**



**Treatment Period 2**



\* Visit also for patients who discontinue IMP early, 7 days after the last dose of IMP

## Table of Contents

<b>Title Page.....</b>	<b>1</b>
<b>1 PROTOCOL SYNOPSIS .....</b>	<b>3</b>
<b>Table of Contents .....</b>	<b>15</b>
<b>List of Appendices.....</b>	<b>20</b>
<b>List of In-text Tables.....</b>	<b>Error! Bookmark not defined.</b>
<b>List of In-text Figures .....</b>	<b>Error! Bookmark not defined.</b>
<b>List of Abbreviations .....</b>	<b>22</b>
<b>Definition of Terms .....</b>	<b>24</b>
<b>2 OBJECTIVES .....</b>	<b>25</b>
2.1    Objectives and Endpoints .....	25
<b>3 BACKGROUND AND RATIONALE .....</b>	<b>27</b>
3.1    Disease.....	27
3.2    Nabiximols Background.....	28
3.3    Rationale.....	28
3.4    Clinical Hypothesis .....	28
<b>4 EXPERIMENTAL PLAN .....</b>	<b>30</b>
4.1    Trial Design.....	30
4.2    Number of Sites .....	31
4.3    Number of Patients .....	31
<b>5 INVESTIGATIONAL MEDICINAL PRODUCT .....</b>	<b>32</b>
5.1    Nabiximols .....	32
5.2    Placebo .....	32
5.3    Packaging, Storage, and Drug Accountability .....	32
5.3.1    Packaging and Labeling.....	32
5.3.2    Storage .....	33
5.3.3    Supply and Return of Investigational Medicinal Product.....	33
5.3.4    Investigational Medicinal Product Accountability .....	34
5.3.5    Post-trial Provision .....	35
<b>6 PATIENT ELIGIBILITY .....</b>	<b>36</b>
6.1    Inclusion Criteria .....	36
6.2    Exclusion Criteria.....	37

<b>7</b>	<b>PATIENT ENROLLMENT</b>	<b>40</b>
7.1	Treatment Assignment .....	40
7.2	Randomization.....	40
<b>8</b>	<b>TREATMENT PROCEDURES</b>	<b>41</b>
8.1	Investigational Medicinal Product Dosage, Administration, and Schedule .....	41
8.1.1	Dose Administration.....	41
8.1.2	Dose Escalation and Dose Adjustments .....	42
8.2	Washout Period .....	43
8.3	Concomitant Therapy .....	43
8.3.1	Concomitant Antispasticity Medications.....	43
8.4	Prohibited Therapy During Trial Period .....	43
8.5	Compliance in Investigational Medicinal Product Administration.....	44
8.6	Access to Blinded Treatment Assignment .....	44
<b>9</b>	<b>TRIAL PROCEDURES</b>	<b>45</b>
9.1	Trial Procedures by Visit.....	45
9.1.1	Screening (Visit 1 [Days -28 to -1]) .....	45
9.1.1.1	Screening Failures.....	46
9.1.2	Treatment Period 1 (Visits 2 to 5 [Days 1 to 21]) .....	47
9.1.2.1	Visit 2 (Day 1).....	47
9.1.2.2	Visit 3 (Day 8, Phone Call).....	48
9.1.2.3	Visit 4 (Day 15) and Visit 5 (Day 21).....	48
9.1.3	Washout Period (Days 22 to 30).....	49
9.1.4	Treatment Period 2 (Visits 6 to 9 [Days 31 to 51]) .....	50
9.1.4.1	Visit 6 (Day 31).....	50
9.1.4.2	Visit 7 (Day 38, Phone Call).....	51
9.1.4.3	Visit 8 (Day 45) and Visit 9 (Day 51, End of Treatment).....	51
9.1.5	Safety Follow-up Visit (Visit 10 [Day 58]) .....	52
9.2	Trial Procedure Listing.....	53
9.2.1	Informed Consent .....	53
9.2.2	Contraception Requirements .....	53
9.2.3	Demographics .....	54
9.2.4	Previous Cannabis Use .....	54
9.2.5	Medical History .....	54
9.2.6	Concomitant Medication .....	54

9.2.7	Physical Examination .....	55
9.2.8	Examination of Oral Mucosa.....	55
9.2.9	Body Weight Measurements.....	55
9.2.10	Vital Signs .....	55
9.2.11	12-Lead Electrocardiogram .....	55
9.2.12	Clinical Laboratory Sampling.....	55
9.2.12.1	Pharmacokinetic Blood Sampling.....	57
9.2.13	Interactive Response Technology .....	57
9.2.14	Electronic Patient Diary .....	57
9.2.14.1	Electronic Diary Training .....	58
9.2.14.2	Spasticity Numerical Rating Scale.....	58
9.2.14.3	Use of Antispasticity Medications and Investigational Medicinal Product Dosing Record .....	58
9.2.15	Questionnaires and Assessments Completed at Scheduled Visits.....	58
9.2.15.1	Modified Ashworth Scale .....	59
9.2.15.2	Multiple Sclerosis Spasticity Scale .....	59
9.2.15.3	Columbia-Suicide Severity Rating Scale .....	59
9.2.15.4	Timed 25-Foot Walk.....	60
9.2.16	Investigational Medicinal Product Accountability .....	60
9.2.17	Adverse Events .....	60
9.2.18	Subject Discontinuation.....	60
9.2.19	Special Circumstances .....	60
<b>10</b>	<b>WITHDRAWAL .....</b>	<b>62</b>
<b>11</b>	<b>URGENT SAFETY MEASURES .....</b>	<b>64</b>
<b>12</b>	<b>ADVERSE EVENT REPORTING .....</b>	<b>65</b>
12.1	Definitions .....	65
12.1.1	Adverse Event.....	65
12.1.2	Investigator .....	65
12.2	Serious Adverse Events.....	65
12.3	Reporting Procedures for Serious Adverse Events .....	66
12.4	Pregnancy .....	67
12.5	Causality Assessment.....	67
12.6	Reporting Procedures for All Adverse Events .....	68
12.7	Follow-up Procedures for Adverse Events.....	69

12.8	Potential Cases of Drug-induced Liver Injury .....	70
12.9	Notification of Safety Information to Investigators, Regulatory Authorities, and Institutional Review Boards/Independent Ethics Committees.....	71
<b>13</b>	<b>STATISTICAL CONSIDERATIONS .....</b>	<b>73</b>
13.1	Sample Size, Power, and Significance Levels .....	73
13.2	Interim Analysis .....	73
13.3	Analysis Sets .....	73
13.3.1	Protocol Deviations .....	74
13.4	General Considerations .....	74
13.5	Accountability and Background Characteristics .....	74
13.5.1	Enrollment and Disposition .....	74
13.5.2	Baseline and Demographic Characteristics .....	74
13.5.3	Medical History .....	75
13.5.4	Concomitant Medication .....	75
13.6	Endpoints and Statistical Methods .....	75
13.6.1	Evaluatable Period .....	75
13.6.2	Primary Endpoint.....	75
13.6.3	Secondary Efficacy Endpoint .....	76
13.6.4	Exploratory Efficacy Endpoints .....	76
13.6.5	Pharmacokinetics .....	76
13.6.6	Safety .....	77
13.6.6.1	Treatment Compliance and Extent of Treatment Exposure.....	77
13.6.6.2	Adverse Events.....	77
13.6.6.3	Clinical Laboratory Data.....	77
13.6.6.4	Vital Signs, 12-Lead Electrocardiogram, Physical Examination, and Other Safety Data.....	78
<b>14</b>	<b>DATA SAFETY MONITORING COMMITTEE.....</b>	<b>79</b>
<b>15</b>	<b>REGULATORY AND ETHICAL OBLIGATIONS .....</b>	<b>80</b>
15.1	Declaration of Helsinki .....	80
15.2	Informed Consent .....	80
15.3	Institutional Review Board/Independent Ethics Committee .....	80
15.4	Pretrial Documentation Requirements .....	81
15.5	Patient Confidentiality.....	81
<b>16</b>	<b>ADMINISTRATIVE AND LEGAL OBLIGATIONS .....</b>	<b>83</b>

---

16.1	Protocol Amendments and End of Trial or Termination.....	83
16.2	Trial Documentation and Storage.....	83
16.3	Trial Monitoring and Data Collection .....	84
16.4	Quality Assurance .....	85
16.5	Compensation.....	85
16.6	Publication Policy.....	85
16.7	Intellectual Property Rights.....	86
16.8	Confidential Information .....	86
<b>17</b>	<b>REFERENCES.....</b>	<b>87</b>

## **List of Appendices**

<b>Appendix 1</b>	<b>SCHEDULE OF ASSESSMENTS .....</b>	<b>88</b>
<b>Appendix 2</b>	<b>TRIAL PERSONNEL.....</b>	<b>92</b>
Appendix 2.1	Investigator Details .....	92
Appendix 2.2	Sponsor Contact Details.....	92
Appendix 2.3	Contract Research Organizations.....	92
<b>Appendix 3</b>	<b>QUESTIONNAIRES/ASSESSMENTS.....</b>	<b>93</b>
<b>Appendix 4</b>	<b>PROHIBITED MEDICATIONS SOLELY METABOLIZED BY UGT1A9 AND UGT2B7.....</b>	<b>94</b>
Appendix 4.1	Prohibited Medications Metabolized Solely by UGT1A9.....	94
Appendix 4.2	Prohibited Medications Metabolized Solely by UGT2B7 .....	94

### **List of In-text Tables**

Table 2-1	Objectives and Endpoints .....	25
Table 8.1.2-1	Example Titration Schedule.....	42
Table 9.2.12-1	Biochemistry, Hematology, Urinalysis, Pregnancy Test, and Drug Screen .....	56
Table 9.2.12.1-1	Pharmacokinetic Blood Sampling Schedule.....	57

### **List of In-text Figures**

Figure 1-1	Trial Design and Treatment Schematic.....	14
------------	---	----

## **List of Abbreviations**

11-COOH-THC	11-carboxy- $\Delta^9$ -tetrahydrocannabinol
11-OH-THC	11-hydroxy- $\Delta^9$ -tetrahydrocannabinol
7-COOH-CBD	7-carboxy-cannabidiol
7-OH-CBD	7-hydroxy-cannabidiol
AD	Assistive device
AE	Adverse event
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
BDS	Botanical drug substance
CBD	Cannabidiol
CI	Confidence interval
CIOMS	Council for International Organizations of Medical Sciences
CRO	Contract research organization
C-SSRS	Columbia-Suicide Severity Rating Scale
ECG	Electrocardiogram
eCRF	Electronic case report form
EU	European Union
FAS	Full Analysis Set
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GW	GW Pharma Ltd
IB	Investigator Brochure
ICF	Informed consent form
ICH	International Council for Harmonisation
IEC	Independent ethics committee
IMP	Investigational medicinal product
INR	International normalized ratio
IRB	Institutional review board
IRT	Interactive response technology
LLMT-4	Lower Limb Muscle Tone-4
LLMT-6	Lower Limb Muscle Tone-6
MAS	Modified Ashworth Scale
MS	Multiple sclerosis

---

MSSS-88	Multiple Sclerosis Spasticity Scale
NRS	Numerical Rating Scale
PI	Principal investigator
PK	Pharmacokinetic
PP	Per Protocol
PRN	As-needed
PT	Preferred term
PVD	Pharmacovigilance department
QoL	Quality of life
R2	Relaxation Index
SAE	Serious adverse event
SAP	Statistical analysis plan
SD	Standard deviation
SOC	System organ class
SUSAR	Suspected unexpected serious adverse reaction
T25FW	Timed 25-Foot Walk
TBL	Total bilirubin
TEAE	Treatment-emergent adverse event
THC	$\Delta^9$ -Tetrahydrocannabinol
ULN	Upper limit of normal
US	United States

## **Definition of Terms**

<b>Term</b>	<b>Definition</b>
Clonus	A clinical manifestation of spasticity described as self-sustained rhythmic involuntary muscular contractions and relaxations in response to a muscle stretch
Completer	A patient who completes both treatment periods
Day 1	The day a patient first receives investigational medicinal product in this trial
End of trial	Last patient last visit or last contact, whichever occurs last
Enrolled patient	Any patient who has provided written informed consent to take part in the trial
International normalized ratio	A calculation made to standardize prothrombin time
Investigational medicinal product	Term used to describe both investigational active product and reference therapy (placebo)
Investigator	Trial principal investigator or a formally delegated trial physician
Lower Limb Muscle Tone-4	A measure of velocity-dependent muscle tone in the lower limbs consisting of the average of the 4 individual MAS transformed scores of knee flexors and knee extensors on both sides of the body
Lower Limb Muscle Tone-6	A measure of velocity-dependent muscle tone in the lower limbs consisting of the average of the 6 individual MAS transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body
Spasm	A clinical manifestation of spasticity described as a sudden, involuntary contraction of a muscle
Spasticity	A velocity-dependent increase in muscle tone resulting from an upper motor neuron lesion. Clinically, spasticity manifests as muscle stiffness or tightness, increased tendon reflexes, clonus, and flexor and extensor spasms
Standardized snack	A meal containing at least 300 kcal (of which approximately 30 kcal is composed of fat)

## **2 OBJECTIVES**

### **2.1 Objectives and Endpoints**

An overview of objectives and endpoints is shown in Table 2-1.

<b>Table 2-1 Objectives and Endpoints</b>	
<b>Primary Objective</b>	<b>Primary Endpoint</b>
<ul style="list-style-type: none"><li>To evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6; LLMT-6) in patients with multiple sclerosis (MS)</li></ul>	<ul style="list-style-type: none"><li>Change in Lower Limb Muscle Tone-6 (LLMT-6; defined as the average of the 6 individual MAS transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body) from Day 1 predose to Day 21 and from Day 31 predose to Day 51</li></ul>
<b>Secondary Objectives</b>	<b>Secondary Endpoints</b>
<ul style="list-style-type: none"><li>To evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-4; LLMT-4) in patients with MS</li></ul>	<ul style="list-style-type: none"><li>Change in Lower Limb Muscle Tone-4 (LLMT-4; defined as the average of the 4 individual MAS transformed scores of knee flexors and knee extensors on both sides of the body) from Day 1 predose to Day 21 and from Day 31 predose to Day 51</li></ul>
<ul style="list-style-type: none"><li>To evaluate the safety and tolerability of nabiximols after administration of multiple doses</li></ul>	<ul style="list-style-type: none"><li>Frequency of treatment-emergent adverse events (TEAEs)</li><li>Change from baseline to each assessment time point by treatment period for the following:<ul style="list-style-type: none"><li>Clinical laboratory parameters</li><li>Vital signs</li><li>Physical examination procedures</li><li>12-lead electrocardiograms (ECGs)</li></ul></li><li>Columbia-Suicide Severity Rating Scale (C-SSRS) at screening, and at each subsequent time point with reference to the last assessment (since last visit)</li></ul>

**Table 2-1      Objectives and Endpoints**

<ul style="list-style-type: none"><li>To evaluate the pharmacokinetic (PK) profile of nabiximols after administration of multiple doses</li></ul>	<ul style="list-style-type: none"><li>Plasma concentrations for <math>\Delta^9</math>-tetrahydrocannabinol (THC) and its relevant metabolites (11-hydroxy-<math>\Delta^9</math>-tetrahydrocannabinol and 11-carboxy-<math>\Delta^9</math>-tetrahydrocannabinol) and cannabidiol (CBD) and its relevant metabolites (7-hydroxy-cannabidiol and 7-carboxy-cannabidiol) at distinct time points during each treatment period (Visits 2, 4, 5, 6, 8, and 9)</li></ul>
<b>Exploratory Objectives</b>	<b>Exploratory Endpoints</b>
<ul style="list-style-type: none"><li>To evaluate the effect of nabiximols after administration of multiple doses on walking using the Timed 25-Foot Walk (T25FW) test</li><li>To evaluate the effect of nabiximols after administration of multiple doses on the following patient-reported outcomes:<ul style="list-style-type: none"><li>The 11-point Numerical Rating Scale (NRS) spasticity score</li><li>Daily spasm count</li><li>The MS Spasticity Scale (MSSS-88) total and subdomain scores</li></ul></li></ul>	<ul style="list-style-type: none"><li>Change in Timed 25-Foot Walk (T25FW) test from Day 1 predose to Day 21 and from Day 31 predose to Day 51</li><li>Average 11-point NRS spasticity score over the last 7 days of each double-blind treatment period</li><li>Average daily spasm count over the last 7 days of each double-blind treatment period</li><li>Total and subdomain scores of the MSSS-88 at the end of the maintenance-dose phase of each double-blind treatment period</li></ul>

**Primary Estimand: the mean treatment difference (nabiximols – placebo) in the change in Lower Limb Muscle Tone-6 (LLMT-6) from Day 1 (predose) to Day 21 and from Day 31 (predose) to Day 51 for all randomized patients.**

### **3 BACKGROUND AND RATIONALE**

#### **3.1 Disease**

Multiple sclerosis is a progressive, chronic, immune-mediated disease of the central nervous system<sup>1,2</sup>, diagnosed predominantly in young adults, with more than 2.3 million people affected worldwide<sup>3</sup>. It is the most common neurological disease in young and middle-aged adults, resulting in marked physical disability, inability to work or early retirement, significantly impaired quality of life (QoL), and a substantial burden on society in terms of associated costs as the disease evolves<sup>4,5</sup>. Multiple sclerosis is clinically characterized by a broad range of signs and symptoms, the most common being restricted mobility, spasticity, fatigue, sensory deficits, weakness, pain, bladder dysfunction, cognitive dysfunction, and visual impairment<sup>6,7</sup>.

The pathology of MS is characterized by autoimmune damage of neuronal axons and destruction of the protective myelin sheath (demyelination). Several signs and symptoms may occur as a consequence of the nerve damage; muscle spasticity (a velocity-dependent increase in muscle tone resulting from an upper motor neuron lesion) is one of the most common manifestations of MS, affecting more than 80% of patients with MS during the course of the disease<sup>6,8,9</sup>. Multiple sclerosis spasticity clinically manifests as symptoms, such as muscle stiffness or tightness, and signs including increased tendon reflexes, clonus, and flexor and extensor spasms mainly in the extensor muscles of the lower limbs and flexor muscles of the upper limbs. On a daily basis, severity may be exacerbated by a range of concurrent medical conditions, such as urinary infections. The QoL of patients with MS worsens as spasticity severity increases<sup>5,10,11</sup>.

The most important goals in the treatment of patients with MS-induced spasticity are to avoid or eliminate triggers that may elicit spasms or enhance spasticity, to reduce pain and symptoms of spasticity, to improve or maintain functional abilities and QoL, and to facilitate nursing. If physiotherapy, as a generally accepted first basic treatment option, is not sufficient, antispasticity medications should be tried<sup>12</sup>. Depending on the severity of generalized spasticity, drug treatment varies widely, reliant on approved drugs that may differ between geographical regions. Commonly used medications such as baclofen, tizanidine, or dantrolene are taken orally. Their mode of action varies, but all cause muscle relaxation.

Both incidence and severity of MS spasticity increase as the disease evolves, appearing in more than 80% of patients with MS and reaching a moderate or severe intensity in over a third of cases despite available treatments<sup>6,13,14</sup>. Multiple sclerosis spasticity of at least moderate severity is present in approximately a third of patients with a 10-year history of the disease<sup>14</sup>.

### **3.2 Nabiximols Background**

The investigational medicinal product (IMP) nabiximols (named Sativex® in Canada, Spain, and the United Kingdom and also named Sativex oromucosal spray; United States [US] Adopted Name: Nabiximols; World Health Organization Anatomical Therapeutic Chemical Code: N02BG10) is formulated from 2 genetically distinct varieties of the *Cannabis sativa* L. plant, which are defined by their chemical profiles (chemotypes). GW Pharma Ltd (GW) produces chemotypes of *Cannabis sativa* L. that contain principally 1 of the 2 major cannabinoids,  $\Delta^9$ -tetrahydrocannabinol (THC) or cannabidiol (CBD). Production under controlled conditions ensures consistency in the starting materials. Dried plant material is extracted and further processed to yield the THC botanical drug substance (BDS) and CBD BDS. The extracts also contain smaller amounts of minor cannabinoids and the non-cannabinoid plant components including alpha- and trans-caryophyllenes, other terpenes, sterols, and triglycerides.

Nabiximols contains amounts of both THC BDS and CBD BDS to yield similar concentrations of THC and CBD, dissolved in the excipients ethanol and propylene glycol, and delivered as an oromucosal spray. Peppermint oil is used in the spray preparation as a flavoring agent to mask the taste and odor of plant-based components present in the product. The oromucosal spray is administered under the tongue or inside the cheeks and delivers 2.7 mg THC and 2.5 mg CBD per 100  $\mu$ L spray.

For more information, refer to the Investigator's Brochure (IB)<sup>15</sup>.

### **3.3 Rationale**

The efficacy of nabiximols in the symptomatic treatment of spasticity associated with MS was originally demonstrated in trials with a primary endpoint based on a patient-reported outcome measure, the 11-point NRS for spasticity. Data indicating efficacy of nabiximols on objective measures of spasticity was limited to change in the MAS, which formed the basis for secondary endpoints in the SAVANT trial and in an investigator-initiated trial<sup>16</sup>. Trial GWSP20105 is being conducted to further evaluate the potential effect of nabiximols on clinical measures of velocity-dependent muscle tone, which may be considered more objective, and more proximate to the pathophysiology of spasticity in patients with MS than the 11-point NRS for spasticity. This trial may support the authorization of nabiximols for the symptomatic treatment of spasticity in additional markets where nabiximols is not currently authorized.

### **3.4 Clinical Hypothesis**

The primary clinical hypothesis is that after administration of multiple doses, there will be a difference between nabiximols and placebo for change in velocity-dependent muscle tone in

the lower limbs as measured by the Lower Limb Muscle Tone-6 (LLMT-6) from predose to end of treatment of each treatment period.

## **4 EXPERIMENTAL PLAN**

### **4.1 Trial Design**

This multicenter, randomized, double-blind, placebo-controlled, 2-treatment, 2-period, Phase 3 crossover trial is being conducted to evaluate the effect of multiple doses of nabiximols on clinical measures in the symptomatic treatment of patients with MS.

Patients with spasticity associated with MS will participate in a screening period of up to 28 days; no changes in the dosing regimen of the patients' current MS antispasticity medications, if any, will be made during this period.

As part of the baseline period of each treatment period, patients will keep an electronic diary to record 11-point NRS spasticity score, spasm count, and use of antispasticity medications once daily, around the same time each day, preferably in the evening before retiring to sleep, for at least 7 days prior to Visits 2 and 6. At Visit 2, in the morning of Day 1, eligible patients will be randomly assigned in a 1:1 ratio to 1 of 2 treatment sequences, each composed of 2 treatment periods, with administration of multiple doses of nabiximols or placebo.

Patients randomized will complete 2 treatment periods with administration of IMP for 21 days per treatment period. Each treatment period will consist of a dose-titration phase of approximately 14 days, followed by a maintenance-dose phase of approximately 7 days, where the individually determined optimized dose level remains unchanged for the remainder of each treatment period after titration. Doses greater than 1 spray/day will be divided into a morning dose and an evening dose.

Throughout both treatment periods, patients will initiate IMP treatment as a single spray in the clinic in the morning of Visits 2 (Day 1) and 6 (Day 31) of each treatment period. Patients will gradually titrate their daily dose by 1 to 2 additional sprays/day to an optimized dose or to a maximum of 12 sprays/day over the first approximately 14 days of treatment with an approximately 15-minute interval between sprays. Patients should complete titration within approximately 14 days of their first dose of IMP in each treatment period and should continue at the same dose level achieved at the end of the titration phase (i.e., their daily optimized dose)  $\pm$  1 spray divided into a morning dose and an evening dose for the remainder of the treatment period. Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays. Patients will be advised to administer IMP at approximately the same time each day in a consistent manner in relation to food consumption. Morning and evening doses should be administered around the same time within 30 minutes after starting a snack or meal.

On the days of scheduled MAS assessments other than Visit 1 (i.e., Visits 2, 5, 6, and 9), patients will attend the trial site without having administered any IMP in the morning. On days of MAS assessment, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before the administration of IMP. Administration of the

morning dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) will occur at the trial site under the supervision of site staff; MAS assessments will occur at scheduled time points before (Visits 2 and 6 [predose]) and after (Visits 2, 5, 6, and 9 [3 hours  $\pm$ 15 minutes postdose]) IMP administration.

A washout period of at least 7 days will separate the 2 treatment periods. During the washout period, patients will continue to take their current MS antispasticity medications, if any, without any changes in dosing regimen.

Patients who complete the 2 treatment periods will complete an End of Treatment Visit (Visit 9). Patients who discontinue IMP early will be encouraged to remain in the study for the duration of the treatment period in which they discontinue IMP and will complete an End of Treatment Visit (Visit 9) at the end of that period. A Safety Follow-up Visit (Visit 10) will occur 7 (+ 3) days after the last dose of IMP or after the End of Treatment visit (Visit 9), whichever is later, for all patients.

A schematic ([Figure 1-1](#)), presented at the end of [Section 1](#), depicts the overall trial design. More detailed information on treatment and trial procedures is provided in [Section 8](#) and [Section 9](#), respectively.

## **4.2 Number of Sites**

Approximately 30 sites are expected to participate in this trial.

## **4.3 Number of Patients**

Ninety-five patients will be randomly assigned to each treatment sequence (nabiximols followed by placebo or placebo followed by nabiximols) to ensure that at least 170 patients in total complete the 2 treatment periods. If more than 20 patients withdraw from the study, additional patients will be enrolled to have at least 170 completers.

## **5 INVESTIGATIONAL MEDICINAL PRODUCT**

Please refer to the separate pharmacy manual for more detailed information on the IMP.

### **5.1 Nabiximols**

Product code: GW-1000-02

Nabiximols is presented as an oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL) as well as other non-cannabinoid plant components, dissolved in ethanol:propylene glycol (50% v/v) excipients with peppermint oil (0.05% v/v) flavoring. Each spray delivers 100 µL of nabiximols.

### **5.2 Placebo**

Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings (FD&C Yellow No.5 [0.0260% v/v], FD&C Yellow No.6 [0.0038% v/v], FD&C Red No.40 [0.0033% v/v], and FD&C Blue No.1 [0.00058% v/v]) and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 µL containing no active ingredients.

### **5.3 Packaging, Storage, and Drug Accountability**

#### **5.3.1 Packaging and Labeling**

The IMP will be manufactured, packaged, labeled, and/or distributed by GW or delegated contractors. The IMP will be presented as an oromucosal spray in a plastic-coated, amber glass vial. The IMP will be dispensed at each relevant visit. A unique identification number will be used to identify each box and the IMP it contains. The unique identification number, together with the packaging reference number, will permit full traceability of manufacture, pack, and label activities conducted at or on behalf of GW and the IMP information held on the interactive response technology (IRT). GW will ensure that all IMP provided is fully labeled and packaged.

Label text will include the following information, as a minimum:

- Sponsor's name and address
- Product identification (e.g., "Nabiximols or Placebo")
- Product details
- Dose and potency
- Vial number
- Batch number
- Trial code
- Site details

- Expiry date
- Storage conditions
- Instruction: “For clinical trial use only”
- Instruction: “Keep out of the sight and reach of children”
- Any other information required by local regulatory authorities

In addition, any local country requirements in accordance with local drug law or regulatory requirement will be included in the final label text.

Directions for use and the name, address, and telephone number of the investigator (of the main contact for information about the product or the clinical trial) will be provided separately to the patient.

### **5.3.2 Storage**

The IMP must be stored in compliance with the local regulations for a controlled drug (if applicable to country). The sponsor must approve storage location and facilities. Temperature records of the trial site storage location must be maintained (recording a minimum of Monday through Friday, excluding public holidays) from the date of receipt of first shipment until the end of the trial dispensing period at each site. These records must contain at least the minimum and maximum daily temperatures and must be made available to the appropriate GW personnel for review throughout the trial. Temperature during transit of IMP to the site must be checked on receipt and compliance/noncompliance to the minimum and maximum recorded.

Should storage conditions deviate from these specified requirements, the GW trial monitor must be contacted immediately to confirm if the IMP remains suitable for use. The IMP must be placed under quarantine until written confirmation is received that the IMP is suitable for use.

Patients should be instructed to store IMP in a refrigerator (2°C to 8°C). Once the spray container is opened and in use, refrigerated storage is not necessary, but the IMP should not be stored above 25°C. The spray container should be stored upright. Patients will be provided with instructions regarding home storage requirements for the IMP.

### **5.3.3 Supply and Return of Investigational Medicinal Product**

The IMP will be transported to approved country depots and trial sites in compliance with good distribution practice guidelines. All IMP will be shipped with a product release certificate that includes a physical description of the product for confirmation of identity on receipt.

Once a site has been activated via the IRT at trial initiation, IMP will be shipped to the identified responsible person, such as the pharmacist, at the investigator’s site, who will

check the amount received (against the IRT Shipment Request) and condition of the drug (i.e., integrity, physical appearance, and temperature during transit). Details of the IMP received will be recorded in the IMP accountability record (see [Section 5.3.4](#)). The site will acknowledge the IMP receipt via the IRT and will complete any receipt forms required. The IMP will be dispensed and returned as detailed in [Section 8.5](#) with further IMP shipments to be initiated by IRT. As directed, all supplies, including unused, partially used, or empty containers, will be returned to GW/depot.

#### **5.3.4      Investigational Medicinal Product Accountability**

The investigator has overall responsibility for the accountability of all used and unused IMP. A drug accountability record for the IMPs must be kept current and must contain the following:

- Trial code
- Batch number/packaging reference number, date of receipt, and quantity of IMP received
- Patient's trial identification number
- Date and quantity of IMP dispensed
- The initials of the dispensing/dosing party
- Date and quantity of IMP returned to the investigator
- IMP expiry dates

The IMP will be dispensed at Visits 2, 4, 6, and 8. Patients will be asked to return all IMP (used and unused) at each subsequent visit (Visits 4, 5, 8, and 9). The trial site will check the returned IMP against the usage recorded in the electronic diary. Any discrepancies will be discussed with the patient at the time of the visit and documented accordingly within the patient's source documents.

The investigator must inform GW promptly of all missing or unaccounted IMP.

A record of returned IMP must be completed and included in the shipment of used and unused IMP to the relevant drug distribution depot. At the end of the trial, a record/statement of reconciliation must be completed and provided to GW.

These inventories must be made available for inspection by an authorized GW representative and local officials or regulatory agency inspectors.

Please refer to the separate pharmacy manual for more detailed information on the IMP.

### **5.3.5 Post-trial Provision**

There will be no post-trial provision of nabiximols.

A summary of the results of this trial will be made available on <http://www.clinicaltrials.gov> as required by US law and on <http://www.clinicaltrialsregister.eu/> of the European Union (EU) Clinical Trials Register.

## **6 PATIENT ELIGIBILITY**

Investigators are responsible for confirming patient eligibility and will be required to maintain a log that includes limited information about all screened patients (initials, age, race, and sex; as allowed per local regulations) and outcome of screening.

### **6.1 Inclusion Criteria**

#### *Screening (Visit 1)*

For inclusion in the trial, patients must fulfill ALL of the following criteria:

- 6.1.1 Male or female, aged 18 years or above.
- 6.1.2 Willing and able to give informed consent for participation in the trial (see [Section 15.2](#)).
- 6.1.3 Willing and able (in the investigator's opinion) to comply with all trial requirements.
- 6.1.4 Has had a diagnosis with any disease subtype of MS, by revised 2017 McDonald criteria, for at least 12 months prior to Visit 1 and is expected to remain stable for the duration of the trial.
- 6.1.5 Has an MAS untransformed score of at least 2 in 2 or more of 6 muscle groups (right knee flexors, left knee flexors, right knee extensors, left knee extensors, right plantar flexors, or left plantar flexors) at Visit 1.
- 6.1.6 If currently receiving approved anti-spasticity therapy, it must be with a stable dosing regimen for at least 30 days prior to Visit 1. The patient must be willing to maintain the same antispasticity medication and not plan to initiate a new course of physiotherapy for the duration of the trial.
- 6.1.7 If currently receiving an approved MS disease-modifying therapy, it must be at a stable dose for at least 3 months prior to Visit 1 and is expected to remain stable for the duration of the trial.
- 6.1.8 If currently receiving dalfampridine or fampridine, it must be at a stable dose for at least 3 months prior to Visit 1 and is expected to remain stable for the duration of the trial.
- 6.1.9 Willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
- 6.1.10 Willing to allow his or her primary care practitioner (if he or she has one) and/or treating neurologist (if he or she has one) to be notified of participation in the trial, if the primary care practitioner/treating neurologist is different from the investigator.

*Additional Inclusion Criteria at Randomization (Visit 2)*

Patients are eligible for randomization in the trial if, in addition to continuing to meet the Screening (Visit 1) inclusion criteria, they also meet the following criterion prior to Visit 2 (Day 1):

6.1.11 Completed at least 5 of 7 days of their electronic diary reporting during the 7 days immediately preceding Visit 2 (Day 1).

## **6.2 Exclusion Criteria**

The patient may not enter the trial if ANY of the following apply:

- 6.2.1 Has taken nabiximols, cannabis, or a cannabis-derived product for medicinal or recreational purposes in the 30 days prior to Visit 1 or unable to abstain for the duration of the study.
- 6.2.2 Did not tolerate or did not respond adequately to treatment with nabiximols or another cannabis-based medication if exposed at any time before the 30-day period prior to Visit 1.
- 6.2.3 Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the patient's level of spasticity.
- 6.2.4 Medical history suggests that relapse/remission is likely to occur during the trial, which, in the opinion of the investigator, is expected to influence the patient's spasticity.
- 6.2.5 Has had a relapse of MS within the 60 days prior to Visit 1.
- 6.2.6 Currently using botulinum toxin injection for the relief of spasticity (within 6 months of Visit 1) or is unwilling to abstain for the duration of the trial.
- 6.2.7 Currently taking antipsychotic medication.
- 6.2.8 Currently taking benzodiazepines unless doses and dosing regimen have been stable for at least 30 days prior to Visit 1.
- 6.2.9 Clinically suspected to have a contracture in one of the muscle groups of the lower limbs, preventing assessment with the MAS.
- 6.2.10 Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP.
- 6.2.11 Has experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months prior to Visit 1 or has a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction.
- 6.2.12 Has a diastolic blood pressure of < 50 mmHg or > 105 mmHg or systolic blood pressure < 90 mmHg or > 150 mmHg (when measured in a sitting position at rest

for 5 minutes) or a postural drop in the systolic blood pressure of > 20 mmHg at Visit 1 or Visit 2. All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.

6.2.13 Has clinically significant impaired renal function at Visit 1, as evidenced by an estimated creatinine clearance lower than 50 mL/min. All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.

6.2.14 Has moderately impaired hepatic function at Visit 1, defined as serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN). All measurements will be performed singly and can be repeated once, if any are outside the reference range but not considered clinically significant.

6.2.15 Male and fertile (i.e., after puberty unless permanently sterile by bilateral orchectomy) unless willing to ensure that he uses male contraception (condom or vasectomy) or remains sexually abstinent during the trial and for 3 months thereafter.

6.2.16 Female and of childbearing potential (i.e., following menarche and until becoming postmenopausal for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that she uses a highly effective method of birth control (e.g., intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence) during the trial and for 3 months thereafter. Patients using combined hormonal methods or a progestogen-only pill or injection or implant should use an additional barrier method such as a condom or diaphragm during the trial and for 3 months thereafter (see [Section 9.2.2](#)).

6.2.17 Female and pregnant (positive pregnancy test at Visit 1 or Visit 2), lactating, or planning pregnancy during the course of the trial or within 3 months thereafter.

6.2.18 Has received an IMP within the 30 days prior to Visit 1.

6.2.19 Has any other clinically significant disease or disorder (including seizure disorder) that, in the opinion of the investigator, may put the patient, other patients, or site staff at risk because of participation in the trial, may influence the interpretation of trial results, or may affect the patient's ability to take part in the trial.

6.2.20 Has any abnormalities identified following a physical examination, clinical laboratory, serology, or other applicable screening procedures that, in the opinion of the investigator, would jeopardize the safety of the patient or the conduct of the study if he or she took part in the trial.

- 6.2.21 Has any history of suicidal behavior in the 5 years prior to Visit 1 or a score of 3, 4, or 5 on the C-SSRS in the month prior to Visit 1.
- 6.2.22 Has donated blood during the 3 months prior to Visit 1 and is unwilling to abstain from donation of blood during the trial.
- 6.2.23 Has been previously randomized into this trial.
- 6.2.24 Has any known or suspected history of alcohol or substance abuse (including opiate abuse) or dependence within 1 year prior to Visit 1.
- 6.2.25 Currently using an illicit drug or current nonprescribed use of any prescription drug.
- 6.2.26 Has a history of psychiatric or neurologic disorder that, in the opinion of the investigator, may interfere with trial participation, data interpretation, or conduct of trial procedures.
- 6.2.27 Has a history of severe psychiatric disorder that may be exacerbated by the use of a cannabinoid-containing product.
- 6.2.28 Has any planned clinical interventions or intends to change any or all medications that may have an effect on spasticity or MS during the trial.
- 6.2.29 Currently taking drugs that are solely metabolized by UGT1A9 and UGT2B7 (see [Appendix 4](#)).
- 6.2.30 Currently taking strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort).

## **7 PATIENT ENROLLMENT**

Before patients may be entered into the trial, GW requires a copy of the relevant site's institutional review board (IRB) or independent ethics committee (IEC) written approval of the protocol, informed consent form (ICF), and other patient information material. Patients will be considered enrolled in the trial from the time of providing written informed consent. All patients must personally sign and date the consent form prior to any procedures being performed (refer to [Section 9.2.1](#) and [Section 15.2](#)).

### **7.1 Treatment Assignment**

At the start of Visit 1, enrolled patients will be allocated a unique patient number in a sequential order by trial site. Following randomization, GW will provide all IMP in a packed and labeled state, and the IRT will identify the pack number to be dispensed to the patient at each relevant visit according to the treatment sequence assigned in the randomization schedule.

### **7.2 Randomization**

The allocation of IMP to treatment number will be done according to a randomization schedule produced by an independent statistician. The randomization schedule will be held centrally on the IRT and not divulged to any other person involved in the trial until the database has been locked and unblinding authorized by the relevant GW personnel. For access to blinded treatment assignment, see [Section 8.6](#). If more than 20 patients withdraw from the study, additional patients will be enrolled to have at least 170 completers.

## **8 TREATMENT PROCEDURES**

### **8.1 Investigational Medicinal Product Dosage, Administration, and Schedule**

The IMP will be presented as a pump oromucosal spray. Nabiximols oromucosal spray is a mixture of THC and CBD extracts derived from *Cannabis sativa* L. Each of the botanical extracts contains a cannabinoid as the major constituent (i.e., THC or CBD) and minor constituents, including other cannabinoid and noncannabinoid plant components, including alpha- and trans-caryohyllenes, other terpenes, sterols, and triglycerides.

The use of placebo in the current trial is deemed necessary to determine the efficacy or safety of the current intervention(s), since the best proven intervention has already been tried/is being given as background treatment and has failed to/does not fully alleviate the patient's symptoms. Placebo to match nabiximols is presented as an oromucosal spray containing excipients, coloring, and flavoring, with no active ingredients.

For details regarding IMP formulations, see [Section 5](#).

#### **8.1.1 Dose Administration**

For all treatment sequences, IMP will be administered by the patient via a pump actuation of oromucosal spray. The IMP will be self-administered to the oral mucosa. Patients will receive IMP dosing training from site staff on Visit 2 (Day 1 predose). Patients will be advised to administer IMP at approximately the same time each day in a consistent manner in relation to food consumption. Morning and evening doses should be administered around the same time within 30 minutes after starting a snack or meal. Patients should divide doses greater than 1 spray/day into a morning dose and an evening dose. On the days of scheduled MAS assessments other than Visit 1 (i.e., Visits 2, 5, 6, and 9), patients will attend the trial site without having administered any IMP in the morning. On the days of MAS assessment, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before the administration of IMP. Administration of the morning dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) will occur at the trial site under the supervision of site staff.

Following the titration phase (see [Section 8.1.2](#)), IMP will be administered as 1 spray (100 µL per spray) with a target interval of approximately 1 minute, until the patient's specific optimized dose has been administered. Patients should be advised to direct each spray at a different site on the oromucosal surface, changing the application site for each spray of the IMP. If lesions are observed or persistent soreness is reported, the IMP administration must be interrupted until complete resolution occurs. Events of this nature are to be recorded according to the adverse event (AE) procedures (see [Section 12](#)).

### **8.1.2 Dose Escalation and Dose Adjustments**

Site staff will demonstrate proper dosing and then observe dosing by the patient at Visit 2 (Day 1) and verify that IMP was correctly administered. Patients will initiate IMP treatment as a single spray in the clinic in the morning of Visits 2 (Day 1) and 6 (Day 31) of each treatment period. Patients will gradually titrate their daily dose to the maximally acceptable dose, balancing efficacy and tolerability, or to a maximum number of 12 sprays/day. During the titration phase, there should be an approximately 15-minute interval between sprays. Patients may temporarily pause or slightly reduce the number of sprays upon the emergence of AEs; the titration may be resumed when the AEs resolve. No further dose adjustments should take place after 14 days unless advised by the investigator. An example titration schedule is presented in [Table 8.1.2-1](#).

Patients should not take more than 12 sprays/day of IMP at any time during the trial. Patients should consult the dosing instructions provided and contact the investigational site when in doubt about changes in the daily dose of IMP at any time during the study.

**Table 8.1.2-1 Example Titration Schedule**

Day	Number of Sprays in the Morning	Number of Sprays in the Evening	Total Number of Sprays/Day
1	1	0	1
2	1	1	2
3	1	2	3
4	2	2	4
5	3	2	5
6	3	3	6
7	4	3	7
8	4	4	8
9	5	4	9
10	5	5	10
11	6	5	11
12	6	6	12
13	6	6	12
14	6	6	12

Patients should complete titration within approximately 14 days of their first dose of IMP in each treatment period and should continue at the same dose level achieved at the end of the titration phase (i.e., their daily optimized dose)  $\pm 1$  spray /day divided into a morning dose and an evening dose for the remainder of the treatment period. This guidance applies unless patients agree with the investigator to lower the dose of IMP to address poor tolerability. Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays.

The total daily dose should be administered as a morning dose and an evening dose, which may be comprised of a different number of sprays during titration. During the period of stable dosing following titration, patients should attempt to achieve a balance in the number of sprays administered as part of the morning and evening doses of IMP.

## **8.2 Washout Period**

Following the final dose of IMP in Treatment Period 1, in the morning of Visit 5 (Day 21), patients will discontinue treatment with IMP for at least 7 days prior to Visit 6 (Day 31). This represents the washout period between the 2 treatment periods of this crossover trial.

## **8.3 Concomitant Therapy**

From Screening (Visit 1) forward, any new treatments taken or any change to ongoing medications during the patient's participation in the trial will be recorded on the appropriate electronic case report form (eCRF) page by the investigator or designee. Similarly, any ongoing physiotherapy as part of the management of spasticity at the time of enrollment will be documented on a separate eCRF page as well as any changes in physiotherapy regimen that occur in the course of the study (e.g., discharge from physiotherapy).

For details about the potential for interactions from initiating IMP with prior medications, refer to the guidance for the investigator and potential drug interactions within the IB<sup>15</sup>.

### **8.3.1 Concomitant Antispasticity Medications**

As nabiximols is being investigated as therapy in patients with spasticity due to MS, patients may currently be taking oral antispasticity medication. If currently receiving approved anti-spasticity therapy, the antispasticity medication must have been stable for at least 30 days prior to Screening (Visit 1) and the medication is expected to remain stable throughout the duration of the trial. The patient must be willing to maintain the same antispasticity therapy and not plan to initiate a new course of physiotherapy for the duration of the trial.

Benzodiazepines use is allowed if doses and dosing regimen have been stable for at least 30 days prior to Visit 1.

If the patient is currently receiving an approved MS disease-modifying therapy or dalfampridine or fampridine, it must be at a stable dose for at least 3 months prior to Visit 1 and is expected to remain stable for the duration of the trial.

## **8.4 Prohibited Therapy During Trial Period**

The following medications are prohibited for the duration of the trial:

- Cannabis use for medical or recreational purposes or any cannabinoid-based medication within 30 days of Visit 1 and for the duration of the trial
- Botulinum toxin injection for the relief of spasticity within 6 months of Visit 1 and for the duration of the trial
- Antipsychotic medication
- Any benzodiazepines use on an as-needed (PRN) basis
- Drugs that are solely metabolized by UGT1A9 and UGT2B7 (see [Appendix 4](#)).

- Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort)

Any patients taking these medications after Visit 1 may be considered for withdrawal from IMP.

## **8.5 Compliance in Investigational Medicinal Product Administration**

The patient will record the number of sprays administered on each treatment day in the electronic diary.

Patients should return all IMP (used and unused) at each of Visits 4, 5, 8, and 9. The electronic diary-reported dosing information and any discrepancies discussed with the patient at the time of the visit will be checked and documented accordingly within the patient's source documents.

Records of IMP accountability will be maintained according to Section 5.3.4.

## **8.6 Access to Blinded Treatment Assignment**

The identity of IMP assigned to patients will be held by the IRT. The principal investigator (PI) at each site, or his or her designee, is responsible for ensuring that information on how to access the IRT for an individual patient is available to the relevant staff in case of an emergency and unblinding is required. A patient's treatment assignment should only be unblinded when knowledge of the treatment is essential to make a decision on the medical management of the patient. Unblinding for any other reason will be considered a protocol deviation.

The investigator is encouraged to contact GW to discuss the rationale for unblinding prior to doing so. However, to prevent delays to the investigator or medical personnel responding to a potentially emergent situation, unblinding of IMP will not be dependent on the investigator receiving approval from GW (i.e., the investigator will be able to obtain the code break information independent of contacting GW).

If the investigator does unblind, he or she must contact GW within 1 working day of the event and must document the time, date, and reason(s) for unblinding in the patient's medical notes and on the eCRF.

## **9 TRIAL PROCEDURES**

A list of the required trial procedures is provided in the subsections that follow; refer also to the schedule of assessments ([Appendix 1](#)). Assessments or tests that are not done and examinations that are not conducted must be reported as such on the eCRF.

Additional procedures to screen for the presence of or immunity against infectious diseases (such as body temperature, sampling of nasal or pharyngeal mucosa or serology) may be conducted at screening, at the beginning of each visit or as needed, according to local guidance and policy; for further details, see [Section 9.2.19](#).

The location of the source data for the following procedures will be documented, per site, in a signed source data verification plan; for further details, see [Section 16.2](#).

In cases where patients are not able to attend study visits due to the presence of an infectious disease or other transmissible condition, the investigator will discuss with the Sponsor potential mitigation approaches (including but not limited to extending the visit window, conducting evaluations via video link or phone call, allowing for safety procedures to be conducted at the patient's home or local facility, or implementing potential mitigation approaches for IMP dispensing, secure delivery, and collection). The rationale (e.g., the specific limitation imposed by the infectious disease that led to the inability to perform the protocol-specified assessment) and outcome of the discussion will be documented in the medical record.

### **9.1 Trial Procedures by Visit**

Patients will be invited to take part in the trial and will be issued with the patient information and informed consent. Following adequate time to discuss the trial with the investigator, nurse, relatives, or caregiver, as wished, patients who provide written informed consent will be screened for entry into the trial.

#### **9.1.1 Screening (Visit 1 [Days -28 to -1])**

Informed consent (see [Section 9.2.1](#)) must be obtained from the patient prior to beginning any trial-related procedures.

The following assessments/procedures will be performed:

- Eligibility check ([Section 6](#))
- Demographics ([Section 9.2.3](#))
- Previous cannabis use ([Section 9.2.4](#))
- Medical history ([Section 9.2.5](#))
- Electronic diary training ([Section 9.2.14.1](#))
- Concomitant medications review ([Section 9.2.6](#))

- AE review ([Section 9.2.17](#))
- Physical examination (including height measurement; [Section 9.2.7](#))
- Oral mucosa examination ([Section 9.2.8](#))
- Body weight measurement ([Section 9.2.9](#))
- Vital signs measurement ([Section 9.2.10](#))
- 12-lead ECG ([Section 9.2.11](#))
- Clinical laboratory blood sampling (hematology and biochemistry) ([Section 9.2.12](#))
- Dipstick urinalysis ([Section 9.2.12](#))
- Urine drug screen (including THC) ([Section 9.2.12](#))
- Serum pregnancy test (if appropriate) ([Sections 9.2.2 and 9.2.12](#))
- Blood THC test ([Section 9.2.12](#))
- MAS assessment ([Section 9.2.15.1](#))
- C-SSRS assessment ([Section 9.2.15.3](#))

The investigator should review the laboratory results as soon as these become available. If the results show that a patient is ineligible, the patient will fail screening.

Following Visit 1, there will be no changes in the dosing regimen of the patient's current oral MS antispasticity medications (if any).

Patients who satisfy all of the inclusion criteria and none of the exclusion criteria specified in [Section 6](#) will enter a baseline period of at least 7 days prior to Visit 2, during which they will be required to take their oral antispasticity medication (if any) and complete an electronic daily diary to record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications once daily, around the same time each day, preferably in the evening before retiring to sleep.

### **9.1.1.1      Screening Failures**

Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently randomly assigned to trial intervention. A minimal set of screen failure information is required to ensure transparent reporting of individuals who failed screening in order to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities. The minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).

Individuals who do not meet the criteria for participation in this trial (screen failure) for reasons such as fever due to a brief acute upper respiratory illness, having taken a prohibited over-the-counter medication within the excluded period, recent blood donation, or who could not be enrolled within the screening window for logistical reasons, may be allowed one opportunity to be rescreened at the discretion of the investigator or designee. The rescreened

patient will be assigned a new patient number and all screening assessments will be repeated. Patients will not be rescreened more than once.

### **9.1.2 Treatment Period 1 (Visits 2 to 5 [Days 1 to 21])**

This treatment period will consist of a dose-titration phase of approximately 14 days followed by a maintenance-dose phase of approximately 7 days, where the individually determined optimized dose level remains unchanged for the remainder of the treatment period after titration. On the days of scheduled MAS assessments other than Visit 1 (i.e., Visits 2 and 5), patients will attend the trial site without having administered any IMP in the morning. On the days of MAS assessment, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before administration of IMP. Patients will continue to take their current oral antispasticity medications without any changes in dosing regimen.

#### **9.1.2.1 Visit 2 (Day 1)**

Patients will return to the site in the morning of Day 1 when eligibility will be confirmed and patients will be randomized.

The following assessments/procedures will be performed on Day 1 predose:

- Eligibility check
- Concomitant medications review
- AE review
- Examination of oral mucosa
- Body weight measurement
- Vital signs measurement
- Urine drug screen (including THC)
- Urine pregnancy test (if appropriate)
- Randomization ([Section 7.2](#))
- PK blood sampling for IMP ([Section 9.2.12.1](#))
- MAS assessment
- T25FW test ([Section 9.2.15.4](#))
- C-SSRS assessment
- IMP dosing training ([Section 9.2.14.3](#))
- IMP dispensing

Following predose assessments and after IMP dosing training and dispensing, site staff will observe dosing by the patient and verify that IMP was correctly administered. Patients will administer a single dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) at the trial site under the supervision of site staff.

The following assessments/procedures will be performed 2 to 4 hours postdose:

- MAS assessment (3 hours  $\pm$ 15 minutes postdose)
- AE review
- Vital signs measurement
- PK blood sampling for IMP ([Section 9.2.12.1](#))

The patient will be provided dosing instructions and advised to contact the investigational site when in doubt about changes in the daily dose of IMP. The patient will be instructed to record IMP doses administered in the patient electronic diary.

The exact time of PK blood sampling and the time of the patient's snacks and meals should be recorded.

Following Visit 2, patients will titrate their daily dose of IMP for approximately 14 days until they achieve an optimized dose with an approximately 15-minute interval between sprays; patients should divide doses greater than 1 spray/day into a morning dose and an evening dose. Administration of the morning and evening doses of IMP should be maintained around the same time each day in a consistent manner in relation to food consumption, i.e., within 30 minutes after starting a snack or meal.

Patients should be reminded to record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications in the electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep. In addition, on the day before Visits 4 and 5, patients will be prompted to record whether they started their morning and evening doses of IMP within 30 minutes of a snack or meal.

Each site will have the option to follow-up with the patient through telephone calls during the titration phase to monitor the patient's titration, safety and tolerance, and electronic daily diary reporting.

### **9.1.2.2 Visit 3 (Day 8, Phone Call)**

Visit 3 will occur 7 days after the first dose of IMP and will consist of a phone call from site staff to patients to monitor adherence with IMP administration and advise on dose titration if required. Concomitant medications and AEs will be collected during this call.

### **9.1.2.3 Visit 4 (Day 15) and Visit 5 (Day 21)**

Visits 4 and 5 will occur 14 and 20 days after the first dose of IMP, respectively. A visit window of  $\pm$ 1 and  $\pm$ 2 days, respectively, from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day, where possible.

Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays. Patients should continue IMP administration at the same dose level achieved at the end of titration (i.e., their

daily optimized dose) ±1 spray divided into a morning dose and an evening dose for approximately 7 days (maintenance-dose phase). Administration of the morning and evening doses of IMP should be maintained around the same time of each day in a consistent manner in relation to food consumption, i.e., within 30 minutes after starting a snack or meal.

On Visit 5, patients will administer their morning dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) at the trial site under the supervision of site staff. The IMP will not be administered in the evening of Visit 5 (Day 21).

The following assessments/procedures will be performed at these visits, unless otherwise indicated:

- MAS assessment (Visit 5 [3 hours ±15 minutes after the first spray of the morning dose] only)
- T25FW test (Visit 5 only)
- Concomitant medications review
- AE review
- Physical examination (Visit 5 only)
- Examination of the oral mucosa
- Vital signs measurement
- 12-lead ECG (Visit 5 only)
- Clinical laboratory sampling (hematology and biochemistry) (Visit 5 only)
- PK blood sampling for IMP ([Section 9.2.12.1](#))
- MSSS-88 assessment (Visit 5 only)
- C-SSRS assessment
- IMP dosing at the investigational site (Visit 5 [morning] only)
- IMP dispensing (Visit 4 only)
- IMP collection and compliance review ([Section 9.2.16](#))

The exact time of PK blood sampling and the time of the patient's snacks and meals should be recorded.

Patients should be reminded to record their 11-point NRS spasticity score, spasm count, use of antispasticity medications, and IMP dosing in the electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep.

### **9.1.3 Washout Period (Days 22 to 30)**

A washout period of at least 7 days will separate the 2 treatment periods. Following the final dose of IMP in Treatment Period 1, in the morning of Visit 5 (Day 21), patients will discontinue treatment with IMP for the 7 days prior to Visit 6 (Day 31). Patients will continue to take their current oral antispasticity medications without any changes in dose. Patients

should be reminded to record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications in the electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep, for at least 7 days prior to Visit 6.

#### **9.1.4 Treatment Period 2 (Visits 6 to 9 [Days 31 to 51])**

This treatment period will consist of a dose-titration phase of approximately 14 days followed by a maintenance-dose phase of approximately 7 days, where the individually determined optimized dose level remains unchanged for the remainder of the treatment period after titration. On the days of scheduled MAS assessments other than Visit 1 (i.e., Visits 6 and 9), patients will attend the trial site without having administered any IMP in the morning. On the days of MAS assessment, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before administration of IMP. Patients will continue to take their current oral antispasticity medications without any changes in dosing regimen.

##### **9.1.4.1 Visit 6 (Day 31)**

Visit 6 will occur 30 days after the first dose of IMP. A visit window of  $\pm 1$  day from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day, where possible.

The following assessments/procedures will be performed on Day 31 predose:

- Concomitant medications review
- AE review
- Examination of oral mucosa
- Body weight measurement
- Vital signs measurement
- Urine pregnancy test (if appropriate)
- PK blood sampling for IMP ([Section 9.2.12.1](#))
- MAS assessment
- T25FW test
- C-SSRS assessment
- IMP dispensing

Following predose assessments and IMP dispensing, patients will administer a single dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) at the trial site under the supervision of site staff.

The following assessments/procedures will be performed 2 to 4 hours postdose:

- MAS assessment (3 hours  $\pm 15$  minutes postdose)
- AE review
- Vital signs measurement

- PK blood sampling for IMP ([Section 9.2.12.1](#))

The patient will be provided dosing instructions and advised to contact the investigational site when in doubt about changes in the daily dose of IMP. The patient will be instructed to record IMP doses administered in the patient electronic diary.

The exact time of PK blood sampling and the time of the patient's snacks and meals should be recorded.

Following Visit 6, patients will titrate their daily dose of IMP for approximately 14 days until they achieve an optimized dose with an approximately 15-minute interval between sprays; patients should divide doses greater than 1 spray/day into a morning dose and an evening dose. Administration of the morning and evening doses of IMP should be maintained around the same time each day in a consistent manner in relation to food consumption, i.e., within 30 minutes after starting a snack or meal.

Patients should be reminded to record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications in the electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep. In addition, on the day before Visits 8 and 9, patients will be prompted to record whether they started their morning and evening doses of IMP within 30 minutes of a snack or meal.

Each site will have the option to follow-up with the patient through telephone calls during the titration phase to monitor the patient's titration, safety and tolerance, and electronic daily diary reporting.

#### **9.1.4.2 Visit 7 (Day 38, Phone Call)**

Visit 7 will occur 7 days after the first dose of IMP during Period 2 and will consist of a phone call from site staff to patients to monitor adherence with IMP administration and advise on dose titration if required. Concomitant medications and AEs will be collected during this call.

#### **9.1.4.3 Visit 8 (Day 45) and Visit 9 (Day 51, End of Treatment)**

Visits 8 and 9 will occur 44 and 50 days after the first dose of IMP, respectively. A visit window of  $\pm 1$  and  $\pm 2$  days, respectively, from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day, where possible.

Once a stable daily dose has been reached, patients should gradually decrease the interval between sprays to a target interval of approximately 1 minute between sprays. Patients should continue IMP administration at the same dose level achieved at the end of titration (i.e., their daily optimized dose)  $\pm 1$  spray divided into a morning dose and an evening dose for approximately 7 days (maintenance-dose phase). Administration of the morning and evening

doses of IMP should be maintained around the same time of each day in a consistent manner in relation to food consumption, i.e., within 30 minutes after starting a snack or meal.

On Visit 9, patients will administer the morning dose of IMP with a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) at the trial site under the supervision of site staff. The IMP will not be administered in the evening of Visit 9 (Day 51).

The following assessments/procedures will be performed at these visits, unless otherwise indicated:

- MAS assessment (Visit 9 [3 hours  $\pm$ 15 minutes after the first spray of the morning dose] only)
- T25FW test (Visit 9 only)
- Concomitant medication review
- AE review
- Physical examination (Visit 9 only)
- Examination of the oral mucosa
- Vital signs measurement
- 12-lead ECG (Visit 9 only)
- Clinical laboratory sampling (hematology and biochemistry) (Visit 9 only)
- PK blood sampling for IMP ([Section 9.2.12.1](#))
- MSSS-88 assessment (Visit 9 only)
- C-SSRS assessment
- IMP dosing at the investigational site (Visit 9 [morning] only)
- IMP dispensing (Visit 8 only)
- IMP collection and compliance review

The exact time of PK blood sampling and the time of the patient's snacks and meals should be recorded.

Patients should be reminded to record their 11-point NRS spasticity score, spasm count, use of antispasticity medications, and IMP dosing in the electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep.

If the decision is made to discontinue IMP early, the patient concerned will be encouraged to remain in the study for the duration of the treatment period in which they discontinue IMP and will complete an End of Treatment Visit (Visit 9) at the end of that period.

### **9.1.5 Safety Follow-up Visit (Visit 10 [Day 58])**

The Safety Follow-up Visit will occur 7 days after the last dose of IMP or after the End of Treatment visit (Visit 9), whichever is later. A visit window of + 3 days from the

scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day, where possible.

The following assessments/procedures will be performed:

- Concomitant medication review
- AE review
- Examination of oral mucosa
- Body weight measurement
- Vital signs measurement
- Dipstick urinalysis
- Serum pregnancy test (if appropriate)
- C-SSRS assessment

## **9.2 Trial Procedure Listing**

### **9.2.1 Informed Consent**

Adult patients with an adequate level of understanding must personally sign and date the IRB/IEC-approved ICF before any trial-specific procedures are performed or any patient-related data are recorded for the trial. If an adult patient is unable to read (illiterate or visually impaired), or is physically unable to speak or write, an impartial witness should be present during the entire informed consent discussion. After the ICF is read and explained to the patient and after the patient has orally consented to participation in the trial and has signed and dated the ICF (if capable of doing so), the witness should also sign and personally date the ICF. By signing the ICF, the witness attests that the information in the ICF was accurately explained to and apparently understood by the patient and that informed consent was freely given by the patient (as outlined in the International Council for Harmonisation [ICH] Tripartite Guideline for Good Clinical Practice [GCP] Topic E6(R2), Section 4.8.9).

If the patient cannot write, they can give consent by “making their mark” on the consent form (e.g., writing an “X”).

The original signed ICF should be retained, and a copy should be provided to the patient. For further details regarding the informed consent, see [Section 15.2](#).

### **9.2.2 Contraception Requirements**

To be eligible for the trial, female patients of childbearing potential (i.e., following menarche and until becoming postmenopausal for  $\geq 12$  consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) must have agreed that they are willing to use highly effective contraception for the duration of the trial and for 3 months thereafter. Highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used

consistently and correctly. Such methods include an intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner (provided that partner is the sole sexual partner of the trial patient and that the vasectomized partner has received medical assessment of the surgical success), or sexual abstinence. Due to the possible interaction of the IMP with contraceptive steroids, the use of hormonal contraception must be supplemented with a barrier method (preferably male condom or diaphragm).

To be eligible for the trial, male patients who are fertile (i.e., after puberty unless permanently sterile by bilateral orchectomy) must have agreed that they are willing to use male contraception (condom or vasectomy) or remain sexually abstinent during the trial and for 3 months thereafter.

Abstinence, as referenced above, is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (calendar, symptothermal, and postovulation methods), withdrawal (coitus interruptus), spermicides only, and the lactational amenorrhea method are not acceptable methods of contraception.

### **9.2.3 Demographics**

At screening (Visit 1), the following information will be obtained for each patient: date of birth, sex, and race (if allowed per local regulations).

### **9.2.4 Previous Cannabis Use**

At Screening (Visit 1), any intermittent or regular previous use of cannabis or cannabinoid products for medical or recreational purposes will be recorded.

### **9.2.5 Medical History**

Relevant, significant medical history will be obtained at Screening (Visit 1) and is defined as any condition or disease that:

- May affect the condition under study in this trial
- Is ongoing on entry into the trial
- Has occurred within 1 year prior to Screening (Visit 1)
- Suspected or confirmed COVID-19 infection (or other significant communicable diseases) within 1 year prior to screening

### **9.2.6 Concomitant Medication**

Details of all current medications will be recorded. Any changes in concomitant medication during the trial must be recorded on the eCRF at trial visits. Patients should stop taking any prohibited therapy prior to Screening (Visit 1), as defined in [Section 8.4](#).

### **9.2.7 Physical Examination**

A full physical examination will be performed at the time points specified in the Schedule of Assessments (see [Appendix 1](#)); height will be recorded at Screening (Visit 1) only.

### **9.2.8 Examination of Oral Mucosa**

Examination of the oral mucosa will occur at relevant visits (see [Appendix 1](#)).

### **9.2.9 Body Weight Measurements**

Body weight measurements will be recorded at relevant visits (see [Appendix 1](#)).

### **9.2.10 Vital Signs**

As part of the screening procedures at Visit 1, vital signs (systolic and diastolic blood pressure and pulse rate) will first be measured after the patient assumed a supine position for 5 minutes. Vital signs will then be measured within 2 minutes of assuming a standing position in ambulatory patients only. At all subsequent time points, vital sign measurements will be completed in a sitting position at rest for 5 minutes. Blood pressure should be recorded using the same arm throughout the trial, where possible.

Additional vital signs measurements may be taken during the trial if clinically indicated.

### **9.2.11 12-Lead Electrocardiogram**

A 12-lead ECG will be performed after 5 minutes in a supine position. A physician must review the ECG (annotated, signed, and dated) and any abnormal findings considered to indicate significant medical history or AEs must be recorded appropriately on the eCRF. Additional ECG measurements can be taken at any time during the trial, if clinically indicated.

### **9.2.12 Clinical Laboratory Sampling**

The investigator and trial monitor will be provided with a list of the normal ranges used by the central clinical laboratory for all variables assayed during the trial and a statement of accreditation (or similar) for the laboratory. Clinical laboratory sample parameters are detailed in [Table 9.2.12-1](#).

All clinical blood samples other than PK sampling will be analyzed at a central clinical laboratory. Urine samples for biochemistry will be analyzed at the trial site by use of a dipstick. In cases where samples cannot be analyzed at the site due to local regulations, a full set of urine samples should be sent to the central clinical laboratory for analysis. Urine sample volume requirements and processing procedures will be detailed in a separate laboratory manual.

<b>Table 9.2.12-1 Biochemistry, Hematology, Urinalysis, Pregnancy Test, and Drug Screen</b>				
<b>Biochemistry (Serum<sup>1</sup>)</b>	<b>Hematology (Whole Blood<sup>1</sup>)</b>	<b>Urinalysis (Urine<sup>2</sup>)</b>	<b>Pregnancy Test (Serum<sup>1</sup>/Urine<sup>2</sup>)</b>	<b>Drug Screen (Serum<sup>1</sup>/Urine<sup>3</sup>)</b>
Alanine aminotransferase	Hematocrit	Blood	Serum and urine	THC
Albumin	Hemoglobin	Glucose		Drugs of abuse
Alkaline phosphatase	Mean cell volume	Nitrites		
Aspartate aminotransferase	Mean corpuscular hemoglobin	pH		
Calcium	Platelets	Protein		
Creatinine	Red blood cell count	White blood cells		
Gamma-glutamyl transferase	White blood cell count with automated differential	Specific gravity		
Potassium		Ketones		
Sodium		Urobilinogen		
Total bilirubin		Bilirubin		
Total protein				
Urea (blood urea nitrogen)				
Prothrombin time (plasma <sup>4</sup> )				

THC =  $\Delta^9$ -tetrahydrocannabinol.

<sup>1</sup> Analyzed at a central laboratory.

<sup>2</sup> Analyzed at the trial site by use of a dipstick (if allowed per local regulations).

<sup>3</sup> The standard drugs of abuse screen, including THC, will be analyzed by use of a urine dipstick at Visits 1 and 2. Patients will undergo a separate blood THC test at Visit 1 only.

<sup>4</sup> Analyzed at Screening (Visit 1) only.

All laboratory results will be reviewed, and the reports signed and dated by an investigator. Any results considered to be of clinical significance must be addressed and followed up as clinically appropriate. The results of blood THC testing at Screening (Visit 1) will be reported back to the trial site for confirmation of eligibility. All laboratory results considered to represent an AE must be documented on the eCRF. For reporting and follow-up of potential cases of drug-induced liver injury, see [Section 12.8](#).

Repeat samples will be taken, if required, for clinical follow-up or if the sample is lost or damaged. Any abnormal end of treatment clinical laboratory result of clinical significance must be repeated at regular intervals until it returns to normal or until an investigator is satisfied that the abnormality is not related to the IMP and needs no further investigation. Blood sample volume requirements and processing procedures will be detailed in a separate laboratory manual; the maximum amount of blood taken during the course of the trial, including PK blood samples, will be approximately 115 mL, taking into account possible repeat tests. If deemed necessary by the investigator or the sponsor, the number and/or volume of blood samples per assessment may be increased as long as the total volume of blood drawn for a subject does not surpass 500 mL (except when extra blood samples need to be taken for safety reasons).

### **9.2.12.1 Pharmacokinetic Blood Sampling**

Plasma concentrations will be obtained for THC and its relevant metabolites (11-OH-THC and 11-COOH-THC) and CBD and its relevant metabolites (7-OH-CBD and 7-COOH-CBD) at distinct time points (Visits 2, 4, 5, 6, 8, and 9). The exact time of PK blood sampling and the time of the patient's snacks and meals should be recorded. On the day before PK blood sampling at Visits 4, 5, 8, and 9, patients will be prompted to record whether they started their morning and evening doses of IMP within 30 minutes of a snack or meal. The PK blood sampling schedule is presented in [Table 9.2.12.1-1](#).

**Table 9.2.12.1-1 Pharmacokinetic Blood Sampling Schedule**

Visit/Day	Time Points
Visit 2/Day 1	Predose and at 0-2 and 2-4 hours postdose
Visit 4/Day 15	0-2 and 2-4 hours postdose
Visit 5/Day 21	Predose and at 0-1 and 2-3 hours postdose
Visit 6/Day 31	Predose and at 0-2 and 2-4 hours postdose
Visit 8/Day 45	0-2 and 2-4 hours postdose
Visit 9/Day 51	Predose and at 0-1 and 2-3 hours postdose

Analysis of all PK samples will be conducted at a central bioanalytical laboratory. Blood sample volume requirements and processing procedures will also be detailed in a separate laboratory manual; the maximum amount of blood taken for PK analyses during the course of the trial will be approximately 75 mL, taking into account possible repeat tests. The patient must be advised that it may not be safe for the patient to undertake further blood tests within 1 month of any trial-related blood draws and to inform the investigator if they suffered any blood loss during the 1-month period leading up to a planned blood draw.

### **9.2.13 Interactive Response Technology**

The IRT will be used to assign patients to treatment sequences, manage IMP supply, and to provide treatment allocation information in the event of patient unblinding.

A member of the trial team must contact the IRT at each clinic visit in order to perform the following:

- Randomize a patient (Visit 2)
- Obtain IMP dispensing information (Visits 2, 4, 6, and 8)
- Provide completion/early withdrawal information (Visit 9)

Training will be given to all sites prior to the start of the trial.

### **9.2.14 Electronic Patient Diary**

As part of the baseline period of each treatment period, patients will record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications in the electronic

diary once daily, around the same time each day, preferably in the evening before retiring to sleep, for at least 7 days prior to Visits 2 and 6.

Throughout the trial, the patient will complete an electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep, to record 11-point NRS spasticity score, spasm count, use of antispasticity medications, and IMP dosing. In addition, on the day before PK blood sampling at Visits 4, 5, 8, and 9, patients will be prompted to record whether they started their morning and evening doses of IMP within 30 minutes of a snack or meal.

#### **9.2.14.1 Electronic Diary Training**

Patients will be trained by the site staff on the use of the electronic diary at Screening (Visit 1) and will be instructed to record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications once daily, around the same time each day, preferably in the evening before retiring to sleep, throughout the baseline period of at least 7 days prior to Visits 2 and 6 and throughout the trial until Visit 9. Following randomization during Visit 2, patients will be instructed to log their daily IMP dosing in the electronic diary throughout the 2 treatment periods until Visit 9.

#### **9.2.14.2 Spasticity Numerical Rating Scale**

The 11-point NRS is considered a valid and reliable method to assess overall spasticity in patients with MS. It is the standardized patient-related outcome that best identifies a clinically important difference and a minimum clinically important difference.

Patients will be asked to make a daily assessment, at bedtime, to read the question, and to tick the most appropriate number to indicate the severity of his or her spasticity over the last 24 hours. The patients will be given a definition of spasticity and the question will be phrased as follows:

*On a scale of 0 to 10, please indicate your level of spasticity over the last 24 hours, considering 0 as “No spasticity” and 10 as “Worst possible spasticity.”*

This information will be recorded in the patient electronic diary.

#### **9.2.14.3 Use of Antispasticity Medications and Investigational Medicinal Product Dosing Record**

Patients will be instructed to record their use of antispasticity medications and their IMP dosing daily in their electronic diary.

#### **9.2.15 Questionnaires and Assessments Completed at Scheduled Visits**

Questionnaires should be completed by the patient, unless otherwise specified. The same person should administer/complete the questionnaires/assessments in order to maintain consistency, unless otherwise stated.

### **9.2.15.1 Modified Ashworth Scale**

The MAS is one of the most widely used methods of measuring spasticity, due in a large part to the simplicity and reproducible method<sup>17</sup> and reflects the findings of a trained observer and not the patients' perception of symptoms.

The MAS has 6 categories to classify muscle spasticity and will be conducted and scored by a blinded, independent, trained, and certified healthcare professional (i.e., one not otherwise involved in the care of the patient within or outside this trial) as follows:

- 0) No increase in muscle tone
- 1) Slight increase in muscle tone, manifested by a catch and release or minimal resistance at end of the range of motion when affected part(s) are moved in flexion or extension
- 1+) Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM)
- 2) More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
- 3) Considerable increase in muscle tone, passive movement is difficult
- 4) Affected part rigid in flexion or extension

The blinded, independent, trained, and certified healthcare professional will perform the MAS assessment, specifically the following 10 muscle groups: hip flexors and adductors, knee flexors and extensors, and plantar flexors on both sides of the body at each time point at specified visits. The same assessor should administer the MAS throughout the trial where possible.

### **9.2.15.2 Multiple Sclerosis Spasticity Scale**

The MSSS-88 is a patient self-report measure of the impact of spasticity (muscle stiffness and spasms) in MS. This 88-item scale captures the patient experience and impact of spasticity, including muscle stiffness, pain and discomfort, muscle spasms, effect on daily activities, ability to walk, body movement, patient feelings, and social functioning. Responses to individual questions can range from "not at all bothered" to "extremely bothered."

### **9.2.15.3 Columbia-Suicide Severity Rating Scale**

The definitions of behavioral suicidal events used in this scale are based on those used in the Columbia Suicide History Form. Questions are asked on suicidal behavior, suicidal ideation, and intensity of ideation. At Screening (Visit 1), questions will be in relation to lifetime experiences (baseline). Questioning at all subsequent visits will be in relation to the last assessment (since last visit).

The C-SSRS is to be administered by the investigator or his or her qualified designee at Visits 1 through 10 as indicated in the schedule of assessments (see [Appendix 1](#)); “qualified designee” is defined as anyone who has completed the C-SSRS training within the past 2 years or has continually administered C-SSRS assessments throughout the trial since obtaining the training certificate. The survey should be completed by the same assessor, where possible, throughout the trial. Assessments will be conducted only if patients are capable of understanding and answering the questions, in the investigator’s opinion.

#### **9.2.15.4 Timed 25-Foot Walk**

The T25FW is a quantitative measure of lower extremity function. A blinded, independent, trained, and certified healthcare professional will perform the T25FW. The same assessor should administer the T25FW test throughout the trial where possible. If ambulatory, the patient will be instructed to begin at one end of a clearly marked 25-foot course. They will be instructed to walk the 25 feet as quickly as possible, but safely, and to not slow down until after they have passed the finish line. The task will be immediately administered a second time following the first trial by having the patient walk back the same distance.

Patients will be permitted to use their customary, nonmotorized assistive device (AD) (cane, walking sticks, walker, and rollator) during the T25FW test. The same AD must be used at each assessment and its use documented in the patient record.

#### **9.2.16 Investigational Medicinal Product Accountability**

Records of IMP accountability will be maintained according to [Section 5.3.4](#).

#### **9.2.17 Adverse Events**

Refer to [Section 12](#) for definitions, procedures, and further information on AE reporting.

#### **9.2.18 Subject Discontinuation**

Patients who are withdrawn (for nondrug related reasons [including COVID-19]) may be replaced following discussion between the investigator and the sponsor. Patients withdrawn as a result of AEs thought to be related to IMP, as determined by the investigator, will generally not be replaced. The decision regarding the replacement of participants will be documented.

#### **9.2.19 Special Circumstances**

During special circumstances (e.g., COVID-19 pandemic), the specific guidance from local public health and other competent authorities regarding the protection of individuals’ welfare must be applied. In cases where participants are not able to perform all protocol-defined assessments due to special circumstances, the investigator must discuss with the sponsor potential mitigation approaches.

For the duration of such special circumstances, the following measures may be implemented for enrolled subjects:

- Safety follow-up may be done by a telephone call, other means of virtual contact or home visit, if appropriate.
- Patient and/or clinician-rated outcomes assessments may be done by videoconference, telephone call, other means of virtual contact, if possible.
- An alternative approach for IMP dispensing, secure delivery and collection may be sought.
- Visits may take place in a different location than defined in the protocol. If this is not feasible, then the visit may take place virtually with documentation of the means of communication (e.g., phone call or videoconference).
- Biological samples may be collected and analysed at a different location than defined in the protocol. Biological samples should not be collected if they cannot be processed in a timely manner or appropriately stored until shipping/processing.
- If despite best efforts it is not possible to collect the biological samples or safety assessments (e.g., ECG, vital signs) within the interval predefined in the protocol (see the Schedule of Assessments Appendix 1), then the interval may be extended up to a maximum length of 7 days.
- If despite best efforts a safety assessment cannot be performed, the investigator must review the benefit-risk for patient continuation in the study and record this in the medical records.

The rationale (e.g., the specific limitation imposed by the special circumstances that led to the inability to perform the protocol-specified assessment) and outcome of the discussion with the sponsor will be documented in the medical record. Information on how each visit was performed will be recorded in the eCRF.

## **10 WITHDRAWAL**

In accordance with the Declaration of Helsinki, the ICH Tripartite Guideline for GCP Topic E6(R2), the US Food and Drug Administration (FDA) regulations relating to GCP and clinical trials, the EU Clinical Trials Directive, the EU GCP Directive, and/or other applicable regulations, a patient has the right to withdraw from the study at any time and for any reason, with no obligation to provide a reason, and without prejudice to his or her future medical care by the physician or at the institution.

The patient must be withdrawn from the trial if any of the following apply:

- Administrative decision by the investigator, GW, or a regulatory authority
- Withdrawal of patient consent
- Lost to follow-up

The patient must cease IMP and should remain in the trial if any of the following apply:

- Pregnancy
- Protocol deviation that is considered to potentially compromise the safety of the patient
- Suicidal behavior or ideation of type 4 or 5 during the treatment period, as evaluated with the C-SSRS
- ALT or AST  $> 3 \times$  ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ( $> 5\%$ )
- ALT or AST  $> 5 \times$  ULN
- ALT or AST  $> 3 \times$  ULN **and** (total bilirubin [TBL]  $> 2 \times$  ULN **or** international normalized ratio [INR]  $> 1.5$ )

The patient may be required to cease IMP at the discretion of the investigator and should remain in the trial for any of the following reasons:

- Did not meet eligibility criteria
- Patient noncompliance
- AE (including clinically significant laboratory result) that, in the opinion of the investigator, would compromise the continued safe participation of the patient in the trial
- Any evidence of drug abuse or diversion
- Disease progression (defined as a relapse of MS requiring a change in treatment)

Should a patient request or decide to withdraw from the study, all efforts must be made to complete and report the observations as thoroughly as possible up to the date of withdrawal. Patients withdrawing due to an AE should be followed up according to [Section 12.7](#). All information should be reported on the applicable eCRF pages (refer to [Section 9.2](#)). A Safety Follow-up Visit should take place 7 (+ 3) days after last dose of IMP or after the End of

Treatment visit (Visit 9), whichever is later (refer to [Section 9.1.5](#)). If withdrawing patients decline to give a reason for withdrawal of consent, the investigator must respect the patients' wishes.

## **11 URGENT SAFETY MEASURES**

The sponsor and investigator may take appropriate urgent safety measures in order to protect the patients of a clinical trial against any immediate hazard to their health or safety. If such measures are taken by the investigator, they must notify GW immediately or at least within 24 hours of awareness. GW will report urgent safety measures to regulatory authorities and will provide a written report to the regulatory authorities and IRB/IEC within 3 days. For information on IMP overdose, please refer to the IB.

## **12 ADVERSE EVENT REPORTING**

### **12.1 Definitions**

#### **12.1.1 Adverse Event**

For the purposes of this trial, an AE is defined as follows:

Any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a preexisting condition that occurs following Screening (Visit 1) and at any point up to the posttreatment Safety Follow-up Visit (Visit 10), which may or may not be considered to be related to the IMP. Any event that is the result of a trial procedure must be recorded as an AE.

Surgical/investigational procedures are not AEs. The medical reason for the procedure is the AE. Elective hospitalizations for pretrial existing conditions or elective procedures are not AEs. An exception may be if the patient has an AE during hospitalization that prolongs his or her scheduled hospital stay, in which case it would be considered a SAE (refer to [Section 12.2](#)).

If reporting a fatal event, the SAE term should be the underlying cause of the death (e.g., disease or medical condition leading to death).

#### **12.1.2 Investigator**

The term investigator refers to the trial PI or a formally delegated trial physician.

### **12.2 Serious Adverse Events**

During clinical investigations, AEs may occur that, if suspected to be IMP related, might be significant enough to lead to important changes in the way the IMP is developed (e.g., change in dose, population, monitoring need, or consent forms). This is particularly true for events that threaten life or function. Such SAEs will be reported promptly to regulatory authorities, applicable IRBs/IECs, and investigators (expedited reporting) by GW.

An AE must only be classed as serious, i.e., an SAE, when the event falls into one of the following criteria:

- Results in death
- Is life-threatening \*
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Is medically significant \*\*

\* The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event that, hypothetically, might have caused death if it were more severe.

\*\* Medical and scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations. Important medical events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

### **12.3 Reporting Procedures for Serious Adverse Events**

All SAEs occurring during the trial must be reported to GW with any other supporting information and recorded in the AE section of the eCRF. Any ongoing SAEs should be followed up until resolution wherever possible. For all deaths, the working diagnosis or cause of death as stated on a death certificate, available autopsy reports, and relevant medical reports should be sent to GW promptly.

**All SAEs must be recorded in the eCRF within 24 hours of discovery or notification of the event.** The GW Pharmacovigilance Department (PWD) will be automatically notified that an SAE has been recorded. Any additional information required for a case (follow-up or corrections to the original case) will be requested by GW PVD through eCRF queries.

The investigator is not obliged to actively monitor for any new SAEs that occurred after the last formal Safety Follow-up Visit (Visit 10). However, if the investigator becomes aware of any deaths or a new IMP-related SAE occurring within 28 days of the final dose of IMP, these should be reported to the GW PVD.

Any other problem discovered after Visit 10 that is deemed to be an unexpected safety issue and is likely to have an impact on patients who have taken part in the trial must be treated as an SAE and reported to the GW PVD. Such posttrial SAEs do not need to be recorded on the patient’s eCRF if editing rights to the eCRF have been removed due to final trial database lock. GW PVD may request safety follow-up information after the final trial visit in order to investigate a potential safety issue.

Contact details for the GW PVD are provided at the front of the site files for all trial sites and upon completion of the GW SAE report form.

## **12.4      Pregnancy**

Any patient, or patient's partner, who has become pregnant while receiving the IMP, or within 3 months of the last dose of IMP, must be reported to the GW PVD. Where possible, the investigator should provide the outcome of the pregnancy.

All pregnancies must be recorded in the eCRF within 24 hours of awareness. The GW PVD will be automatically notified that a pregnancy has been recorded. Any additional information required for a case (follow-up or corrections to the original case) will be requested by GW PVD through eCRF queries.

The investigator is not obliged to actively monitor for any pregnancies that commence more than 3 months after the final dose of IMP. However, if the investigator becomes aware of a new pregnancy outside this time limit, then he/she should report it as above. The GW PVD will follow-up for all pregnancy outcomes.

## **12.5      Causality Assessment**

Causality assessment is required for all AEs and SAEs. Causality assessment must only be assigned by the investigator. All cases judged as having a reasonable suspected causal relationship to the IMP must be reported as such. The expression "*reasonable causal relationship*" is meant to convey in general that there are facts (evidence) or arguments to suggest a causal relationship.

The following question, which must be answered by the investigator for all AEs, is used to capture the reasonable causal relationship of an event to the IMP:

*"In your opinion, is there a plausible relationship to the IMP?"* The answer is either "yes" or "no."

Events that start before the first dose of IMP (pretreatment) should be considered as not causally related. Where a pretreatment event worsens in severity following the first dose of IMP, a new event record should be entered into the eCRF.

Considering the explanation given above, investigators are strongly encouraged to express their opinion on what the cause of an AE might be. For individual patients, the investigator is usually in the best position to assess the underlying suspected cause of an AE. For all AEs and especially SAEs, it is important that the investigator assess not only the possible role of the IMP but also other potential contributing factors. Factors for consideration of the underlying cause may include the following:

- Medical and disease history
- Lack of efficacy/worsening of treated condition
- Concomitant or previous treatment
- Withdrawal of IMP
- Protocol-related procedure

## **12.6 Reporting Procedures for All Adverse Events**

All AEs (including SAEs) occurring during the trial will be reported on the running logs in the AE section of the eCRF. This includes all events from the time following Screening (Visit 1) up to and including the Safety Follow-up Visit (Visit 10), whether or not attributed to IMP and observed by the investigator or patient.

The following information will need to be provided for all AEs:

### **A) Adverse Event (Diagnosis or Syndrome if Known or Signs and Symptoms)**

Where the investigator cannot determine a diagnosis, signs or symptoms should be recorded in the AE section of the eCRF. Once a diagnosis has been determined, the AE section of the eCRF must be updated to reflect the diagnosis in replacement of the original symptoms. In circumstances where only a provisional diagnosis is possible (working diagnosis), the eCRF must be updated to reflect the provisional diagnosis in replacement of the original symptoms. In some circumstances, it may be relevant for the investigator to include the symptoms alongside the diagnosis in the verbatim event description. However, the diagnosis (full or provisional) should be clearly stated, e.g., symptom due to disease (i.e., weakness due to cancer, tremor due to MS, headache and fever due to pneumonia, and generalized weakness due to hepatic cancer progression).

### **B) Adverse Event Start Date and Stop Date**

The start and stop dates of the event must be provided. All AEs require these fields to be completed in full. Partial dates or missing dates are not normally acceptable, and significant effort must be undertaken to obtain any unknown information. If a precise date is not known, an estimated date should be provided instead. When a complete date cannot be given, much information as possible (i.e., month and year or, in exceptional circumstances, just year) should be recorded. When the actual start date becomes known, the eCRF must be updated to replace the previously recorded date.

**C)      Outcome**

The outcome of the event must be recorded accurately and classified into one of the following categories:

- Recovered/Resolved
- Recovered/Resolved with Sequelae
- Not Recovered/Not Resolved
- Fatal

**D)      Severity**

When describing the severity of an AE, the terms mild, moderate, or severe should be used. Clinical judgment should be used when determining which severity applies to any AE.

If the severity of an AE fluctuates day-to-day, e.g., a headache or constipation, the change in severity should not be recorded each time; instead, only the worst observed severity should be recorded with AE start and stop dates relating to the overall event duration, regardless of severity.

A severe AE is not the same as an SAE. For example, a patient may have severe vomiting, but the event does not result in any of the SAE criteria above. Therefore, it should not be classified as serious.

**E)      Causality**

See [Section 12.5](#) above.

**F)      Action Taken With Trial Medication**

This question refers to the action taken with the IMP due to an AE. The action with the IMP must be classed as follows:

- Dose Not Changed
- Dose Reduced
- Drug Interrupted
- Drug Withdrawn

**12.7     Follow-up Procedures for Adverse Events**

The investigator may be asked to provide follow-up information to the GW PVD for any AEs reported or during the investigation of potential safety issues. Such requests for additional safety information may occur after Visit 10, after the trial.

Adverse events considered related to the IMP by the investigator or the sponsor should be followed up until resolution or the event is considered stable.

It will be left to the investigator's clinical judgment whether or not an AE is of sufficient severity to require the patient's withdrawal from treatment. A patient may also voluntarily

withdraw from treatment due to what he or she perceives as an intolerable AE. Further details of withdrawal are presented in [Section 10](#). If either of these occurs, the patient must undergo an end-of-treatment assessment and be given appropriate care under medical supervision until symptoms cease or the condition becomes stable. If a safety concern is identified following withdrawal of a patient, GW may contact the investigator for additional follow-up information.

## **12.8 Potential Cases of Drug-induced Liver Injury**

All trial sites are required to submit to the GW PVD the laboratory results of any patient after randomization who meets the criteria for the following selected laboratory parameters:

- ALT or AST  $> 3 \times \text{ULN}$  with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ( $> 5\%$ )
- ALT or AST  $> 8 \times \text{ULN}$
- ALT or AST  $> 5 \times \text{ULN}$  for more than 2 weeks
- ALT or AST  $> 3 \times \text{ULN}$  **and** (TBL  $> 2 \times \text{ULN}$  **or** INR  $> 1.5$ )

These reports must be sent to the GW PVD via email within 24 hours of awareness of the results (see [Appendix 2](#) for GW PVD contact details). In addition, a copy of the patient's baseline laboratory results together with all reports must be sent to the GW PVD. Any laboratory results that constitute an AE in the investigator's opinion must be recorded in the eCRF. Where the results are considered to be SAEs, these must be recorded in the eCRF within 24 hours of becoming aware of the result, in line with reporting procedures for SAEs ([Section 12.3](#)).

Abnormal values in AST and/or ALT concurrent with abnormal elevations in TBL that meet the criteria outlined above are considered potential cases of drug-induced liver injury and will be considered as protocol-defined criteria for IMP discontinuation and important medical events. The investigator will arrange for the patient to return to the trial site as soon as possible (within 24 hours of notice of abnormal results) for repeat assessment of ALT, AST, TBL, alkaline phosphatase, gamma-glutamyl transferase, INR, and hematology parameter levels; detailed history; and physical examination. Patients should be followed this way until all abnormalities have normalized (in the investigator's opinion) or returned to the baseline state.

Elevations in ALT or AST  $> 3 \times \text{ULN}$  **or** TBL  $> 2 \times \text{ULN}$  alone are not considered potential cases of drug-induced liver injury, but will be followed as detailed above, within 72 hours' notice of abnormal results. If the patient cannot return to the trial site, repeat assessments may be done at a local laboratory and the results sent to GW PVD.

## **12.9      Notification of Safety Information to Investigators, Regulatory Authorities, and Institutional Review Boards/Independent Ethics Committees**

In accordance with the EU Clinical Trials Directive, relevant parts of the FDA Code of Federal Regulations, and any national regulations, GW will inform investigators, regulatory authorities, and relevant IRBs/IECs of all relevant safety information. This will include the reporting of relevant SAEs and all suspected unexpected serious adverse reactions (SUSARs).

This information will be provided through 3 sources:

- 1) IB<sup>15</sup>: this document is a compilation of the clinical and nonclinical safety data available on the IMP that are relevant to the trial. The IB is updated annually.
- 2) Development core safety information: this document forms the safety section of the IB<sup>15</sup> or is updated as an addendum to the IB<sup>15</sup>. This document is revised, if necessary, when new important safety information becomes available.
- 3) Council for International Organizations of Medical Sciences (CIOMS) reports: these reports are issued every time a SUSAR is reported to GW. These provide information on individual case reports and are sent to all the regulatory authorities, the relevant central ethics committees that have approved the trial, and the investigators. As required, the investigator should notify their regional IRBs/IECs of SAEs or SUSARs occurring at their trial site and other AE reports, i.e., CIOMS reports and any additional safety documentation received from GW, in accordance with local procedures.

In the US, investigators are normally required to report promptly to their IRBs all unanticipated problems involving risks to patients or others, including AEs that should be considered unanticipated problems. Based on current FDA guidance, the following clarification is provided in determining what constitutes an unanticipated problem:

In general, an AE observed during the conduct of a trial should be considered an unanticipated problem involving risk to patients and reported to the IRB *only* if it were unexpected, serious, and would have implications for the conduct of the trial (e.g., requiring a significant, and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring requirement, informed consent, or IB). An individual AE occurrence *ordinarily* does not meet these criteria because, as an isolated event, its implications for the trial cannot be understood.

The FDA guidance states that, accordingly, to satisfy the investigator's obligation to notify the IRB of unanticipated problems, any investigators participating in a multicenter trial may

rely on the sponsor's assessment and provide to the IRB a report of the unanticipated problem prepared by the sponsor.

GW will inform investigators, regulatory authorities, and relevant IRBs/IECs of any safety issues or case reports that are considered to be unanticipated and provide such reports as mentioned above. It should be noted that a single SUSAR report notified to investigators in the trial does not necessarily constitute an unanticipated problem unless identified by GW in the submission cover letter.

As a minimum, the recipient will be sent all of the above and relevant updates between the period from ethical approval and final database lock.

## **13 STATISTICAL CONSIDERATIONS**

Further details of the proposed statistical analysis will be documented in a statistical analysis plan (SAP), which will be produced prior to unblinding of the trial. Any deviations from the original SAP will be described in the final clinical study report.

### **13.1 Sample Size, Power, and Significance Levels**

Approximately 95 patients will be randomly assigned to each treatment sequence to ensure that at least 170 patients in total complete the 2 treatment periods. This assumes a true difference of -0.18, and standard deviation (SD) for paired differences of 0.71 for 90% power.

If more than 20 patients withdraw from the study, additional patients will be enrolled to have at least 170 completers.

The primary comparison will be the estimate of the mean treatment difference between nabiximols and placebo in the mean change from baseline in Lower Limb Muscle Tone-6 (LLMT-6).

SAS software version 9.4 was used to perform the sample size calculations.

### **13.2 Interim Analysis**

No formal interim analysis will be conducted. However, additional data, collected outside of this trial, may become available during study conduct. Based on such data, the sample size may be recalculated using a blinded reassessment and updated assumptions of treatment effect and variability, while maintaining study blind and type 1 error.

### **13.3 Analysis Sets**

The following analysis sets will be used for the statistical analysis:

#### **Full Analysis Set**

- All patients who signed the informed consent and were randomized, received at least 1 dose of IMP in the trial, and have post-baseline efficacy data will be included and analyzed according to their randomized treatment.
- The Full Analysis Set (FAS) is the primary analysis set for all efficacy endpoints.

#### **Pharmacokinetic Analysis Set**

- All patients who have received at least 1 dose of IMP and provided sufficient bioanalytical data to calculate reliable (based on the judgement of the pharmacokineticist) estimates of the PK parameters will be included in the PK Analysis Set.

## **Safety Analysis Set**

- All patients who received at least 1 dose of IMP in the trial will be included in the Safety Analysis Set and analyzed according to the treatment received. Only patients for whom it has been confirmed that they did not take IMP will be excluded from the Safety Analysis Set. The Safety Analysis Set will be used to report all safety data.

## **Per Protocol Analysis Set**

If there are a sufficient number of significant protocol deviations in the trial, a Per Protocol (PP) Analysis Set may also be presented. The PP Analysis Set is defined as follows:

A subset of the FAS that includes all patients who have completed the trial with no major protocol deviations deemed to compromise the assessment of efficacy. Major protocol deviations will be identified and fully defined prior to unblinding of the trial. The PP analysis will only be conducted on efficacy endpoints and patients analyzed according to their randomized treatment.

### **13.3.1 Protocol Deviations**

Protocol deviations will be listed, and reasons for exclusion from the analysis sets (for major protocol deviations) will be summarized.

## **13.4 General Considerations**

Unless stated otherwise, continuous variables will be summarized showing the number of non-missing values (n), mean, SD, median, minimum, and maximum. Categorical variables will be summarized showing the number and percentage of patients falling in each category.

For patient electronic diary-based endpoints, baseline is defined as the average of the last 7 days of electronic diary entries prior to randomization (Visit 2).

For clinic-based endpoints, baseline is defined as the last record or measure collected prior to the first dose of IMP in each treatment period.

## **13.5 Accountability and Background Characteristics**

### **13.5.1 Enrollment and Disposition**

All patients (screened, received IMP, prematurely terminated IMP, etc.) will be accounted for in the enrollment and disposition summary tables.

### **13.5.2 Baseline and Demographic Characteristics**

Age, sex, race (per local data protection laws), and other demographic or baseline characteristics will be summarized by treatment sequence using appropriate summary statistics. There will be no formal comparison of baseline data.

### **13.5.3 Medical History**

Previous and current medical conditions will be summarized by system organ class (SOC) and preferred term (PT) by treatment sequence.

### **13.5.4 Concomitant Medication**

Prior medication will be summarized by treatment sequence and concomitant medications taken during the trial will be summarized by treatment period.

## **13.6 Endpoints and Statistical Methods**

The primary efficacy endpoint will be analyzed as detailed in [Section 13.6.2](#). The secondary efficacy endpoint will be analyzed as detailed in [Section 13.6.3](#). The exploratory efficacy endpoints will be analyzed as detailed in [Section 13.6.4](#). The PK data will be summarized as detailed in [Section 13.6.5](#). Safety endpoints will be summarized as detailed in [Section 13.6.6](#).

### **13.6.1 Evaluable Period**

The evaluable period starts on the day of randomization. The end of the evaluable period is defined as the Safety Follow-up Visit (Visit 10).

### **13.6.2 Primary Endpoint**

The primary endpoint is the change in LLMT-6 from Day 1 predose to Day 21 and from Day 31 predose to Day 51. The MAS scores are transformed using the following algorithm: MAS untransformed [to MAS transformed] scores; 0[0], 1[1], 1+[2], 2[3], 3[4], and 4[5].

The primary estimand involves the mean treatment difference (nabiximols – placebo) in the mean change from baseline in LLMT-6 from Day 1 (predose) to Day 21 and from Day 31 (predose) to Day 51 for all randomized patients.

For any given patient, at a given visit, the LLMT-6 will be set to missing if individual MAS transformed scores are missing for 3 or more of the 6 specified muscle groups.

The change from baseline in LLMT-6 will be analyzed using a linear mixed-effects model for crossover data. The model will include a period level LLMT-6 baseline covariate, and treatment, period, and treatment sequence as fixed effects, and patient nested within treatment sequence as a random effect. Mean change from baseline in LLMT-6 will also be summarized by treatment sequence, over time.

The least squares mean estimates for each treatment, along with the standard error and 95% confidence intervals (CIs), will be presented. In addition, estimate of the mean treatment difference in change from baseline in LLMT-6 will be presented along with standard errors of the difference and 95% CIs.

If the data appear to not be normally distributed, alternative approaches such as transformation of the data and nonparametric analyses may be considered to express treatment effects. This will be specified in detail in the SAP.

Further details of statistical analyses will be elaborated in the SAP.

### **13.6.3 Secondary Efficacy Endpoint**

The change in Lower Limb Muscle Tone-4 (LLMT-4; defined as the average of the 4 individual MAS transformed scores of knee flexors and knee extensors on both sides of the body) from Day 1 predose to Day 21 and from Day 31 predose to Day 51 will be analyzed in a similar way to the primary endpoint.

For any given patient, at a given visit, the LLMT-4 will be set to missing if individual MAS transformed scores are missing for 2 or more of the 4 specified muscle groups. To control for Type 1 error, the primary efficacy endpoint and the secondary efficacy endpoint will be tested hierarchically, starting with the primary efficacy endpoint and followed by the secondary efficacy endpoint. No adjustments for multiplicity will be made for other secondary or exploratory endpoints.

### **13.6.4 Exploratory Efficacy Endpoints**

The exploratory endpoints are as follows:

- Change in Timed 25-Foot Walk (T25FW) test from Day 1 predose to Day 21 and from Day 31 predose to Day 51
- Average 11-point NRS spasticity score over the last 7 days of each double-blind treatment period
- Average daily spasm count over the last 7 days of each double-blind treatment period
- Total and subdomain scores of the MSSS-88 at the end of the maintenance-dose phase of each double-blind treatment period

These endpoints will be analyzed using the methods used for the primary endpoint described in [Section 13.6.2](#) and this will be detailed in the SAP.

### **13.6.5 Pharmacokinetics**

Plasma concentration for THC and its relevant metabolites (11-OH-THC and 11-COOH-THC) and CBD and its relevant metabolites (7-OH-CBD and 7-COOH-CBD) will be summarized by treatment period together with any estimates of PK parameters.

This data will undergo a population PK analysis and will be presented in a stand-alone report.

### **13.6.6 Safety**

The safety endpoints are listed below and will be compared with placebo as detailed in the following subsections:

- Frequency of TEAEs
- Change from baseline to each assessment time point by treatment period for the following:
  - Clinical laboratory parameters
  - Vital signs
  - Physical examination procedures
  - 12-Lead ECGs
- Columbia-Suicide Severity Rating Scale (C-SSRS) will be summarized at screening, and at each subsequent time point with reference to the last assessment (since last visit)

#### **13.6.6.1 Treatment Compliance and Extent of Treatment Exposure**

Treatment compliance and exposure to treatment will be summarized.

#### **13.6.6.2 Adverse Events**

Adverse events will be coded according to the Medical Dictionary for Regulatory Activities dictionary.

A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP.

Descriptive presentations of TEAEs will be given by PT and SOC for the Safety Analysis Set. The number of patients reporting at least 1 TEAE will be provided.

The following summaries will be produced at a minimum:

- All-causality TEAEs
- Treatment-related TEAEs
- All-causality TEAEs by maximal severity
- All-causality serious TEAEs
- Treatment-related serious TEAEs
- TEAEs reported as leading to permanent cessation of IMP
- Fatal TEAEs

#### **13.6.6.3 Clinical Laboratory Data**

Clinical laboratory data at Screening, during, and at the end of treatment and the change from baseline to end of treatment will be summarized for the Safety Analysis Set using appropriate

summary statistics. Categorical shift tables will also be presented showing the numbers of patients with values outside the normal range. Changes from baseline to each visit will be summarized.

#### **13.6.6.4     Vital Signs, 12-Lead Electrocardiogram, Physical Examination, and Other Safety Data**

Vital signs, 12-lead ECG, physical examination, and C-SSRS data will be summarized for the Safety Analysis Set at screening, baseline, and each time point during the treatment period using appropriate summary statistics, as applicable. Changes in vital signs from baseline to each assessment post-baseline will also be summarized.

## **14 DATA SAFETY MONITORING COMMITTEE**

There will not be a data safety monitoring committee involved in this trial.

## **15 REGULATORY AND ETHICAL OBLIGATIONS**

### **15.1 Declaration of Helsinki**

The investigator will ensure that this trial is conducted in full conformity with the current version and subsequent amendments of the Declaration of Helsinki, the ICH Tripartite Guideline for GCP Topic E6(R2), the EU Clinical Trials Directive, the EU GCP Directive, and the clinical trial regulations adopting European Commission Directives into national legislation.

### **15.2 Informed Consent**

Initial master informed consent will be prepared by GW and provided to the investigator, who will tailor this for their trial site by adding the site's contact details and by using headed paper. The GW clinical manager will communicate updates to the template by letter. The written informed consent document should be prepared in the language(s) of the potential patient population.

Before a patient's involvement in the trial, the investigator is responsible for obtaining written informed consent from the patient after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the trial and before any trial-specific procedures are performed or any patient-related data are recorded for the trial. The patient must have ample time to consider the information provided before giving written consent. More specific definitions of "ample time" may be in force if required by IRBs/IECs or local regulations.

The acquisition of informed consent must be documented in the patient's medical records, and the ICF must be signed and personally dated by the patient and by the person who conducted the informed consent discussion. The original signed ICF should be retained and a copy should be provided to the patient.

### **15.3 Institutional Review Board/Independent Ethics Committee**

A copy of the protocol, proposed ICFs, master ICF, other patient information material, any proposed advertising material, and any further documentation requested must be submitted to the IRB/IEC for written approval. GW must receive a copy of the written approval of the appropriate version of the protocol and ICF before recruitment of patients into the trial and shipment of IMP.

The investigator must submit and, where necessary, obtain approval from the IRB/IEC for all subsequent protocol amendments and changes to the informed consent document. The investigator must notify the IRB/IEC of deviations from the protocol, SAEs occurring at the trial site, and other AE reports received from GW, in accordance with local procedures.

The investigator will be responsible for obtaining ongoing IRB/IEC approval/renewal throughout the duration of the trial. Copies of the investigator's reports and the IRB/IEC continuance of approval must be sent to GW.

#### **15.4 Pretrial Documentation Requirements**

The investigator is responsible for forwarding the following documents to GW for review before allowing any patients to consent for entry into the trial:

- Signed and dated protocol signature page
- Copy of IRB/IEC-approved ICF (including version number and date) and other patient information material
- Copy of the IRB/IEC approval of the protocol, ICF (including version number and date), and other patient information material
- Up-to-date curricula vitae and medical licenses (per local regulations) of the PI and all subinvestigators
- The IRB/IEC composition and/or written statement of the IRB/IEC in compliance with the FDA regulations relating to GCP and clinical trials, the EU Clinical Trials Directive, the EU GCP Directive, or the ICH Tripartite Guideline for GCP Topic E6(R2), where the EU Clinical Trials and GCP Directives do not apply
- Signed and dated laboratory normal ranges and documentation of laboratory certification (or equivalent) unless using central laboratory arranged by GW
- Signed and dated clinical trial agreement (including patient/investigator indemnity insurance and financial agreement)
- Form FDA 1572, if required
- Drug Enforcement Administration license (where applicable)
- Completed financial disclosure statements for the PI and all subinvestigators, if relevant

GW will ensure that the trial site is informed of when screening of patients can commence.

#### **15.5 Patient Confidentiality**

The investigator must ensure that the patient's anonymity is maintained. In the eCRFs and within electronic data capture databases used to collect the trial data or other documents submitted to GW, patients should be identified by their year of birth and race (if allowed per local regulations). Documents that are not for submission to GW, e.g., signed ICFs, should be kept in strict confidence by the investigator.

In compliance with the FDA regulations relating to GCP and clinical trials and the EU Clinical Trials Directive/ICH Tripartite Guideline for GCP Topic E6(R2), it is required that the investigator and institution permit authorized representatives of the company, the regulatory authorities, and the IRB/IEC to have direct access to review the patient's original

medical records for verification of trial-related procedures and data. Direct access includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the trial. The investigator is obligated to inform the patient that his or her trial-related records will be reviewed by the above-named representatives without violating the confidentiality of the patient.

All information concerning the IMP and operations of GW such as patent applications, formulae, manufacturing processes, basic scientific data, or formulation information supplied to the investigator by the company and not previously published is considered confidential by the company and shall remain the sole property of the company. The investigator will agree to use this information only in accomplishing the trial and will not use it for any other purposes without the written consent of the company.

## **16 ADMINISTRATIVE AND LEGAL OBLIGATIONS**

### **16.1 Protocol Amendments and End of Trial or Termination**

Protocol amendments must be made only with the prior approval of GW. Agreement from the investigator must be obtained for all protocol amendments and amendments to the informed consent document. The IRB/IEC and regulatory authorities must be informed of all amendments and give approval for any substantial amendments. Amendments for administrative changes can be submitted to the IRB/IEC for information only. The investigator must send a copy of the approval letter from the IRB/IEC to GW.

Both GW and the investigator reserve the right to terminate the trial according to the clinical trial agreement. The investigator must notify the IRB/IEC in writing of the trial's completion or early termination and send a copy of the notification to GW.

### **16.2 Trial Documentation and Storage**

The investigator must maintain a list of appropriately qualified persons to whom he/she has delegated trial duties. All persons authorized to make entries in and/or corrections to eCRFs will be included on the GW Delegation of Authority and Signature form.

Source documents are original documents, data and records containing all protocol-specified information from which the patient's eCRF data are obtained. These include, but are not limited to, hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence. A source data verification plan, identifying the source for each data point at each trial site, will be agreed upon with each trial site prior to patient recruitment. In the rare situations of data being recorded directly into the eCRF in error, then the source data from the eCRF should be transcribed into the patient's notes with appropriate signature and date to provide a full audit trail.

The investigator and trial staff are responsible for maintaining a comprehensive and centralized filing system of all trial-related, essential documentation (as outlined in the ICH Tripartite Guideline for GCP Topic E6(R2), Section 8.2), suitable for inspection at any time by representatives from GW and/or applicable regulatory authorities. Elements should include the following:

- Patient files containing completed eCRFs, ICFs, and supporting copies of source documentation
- Trial files containing the protocol with all amendments, IB, copies of pretrial documentation (see [Section 15.4](#)), and all correspondence to and from the IRB/IEC and GW
- Enrollment log of all patients who consented to take part in the trial
- Screening and recruitment log of all patients screened and whether or not they were recruited into the trial (i.e., randomized and/or dosed with IMP)

- Proof of receipt, IMP accountability record, return of IMP for destruction, final IMP reconciliation statement, and all drug-related correspondence

In addition, all original source documents supporting entries in the eCRFs and electronic diary data must be maintained and be readily available.

Following completion or termination of a clinical trial, GW will initiate proper archive of clinical trial-related documentation and electronic records generated by the investigator and/or GW. All clinical trial-related documents and electronic records will be retained within an archiving system for a period dependent on need and for a minimum of 25 years. Essential documents must be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the IMP. These documents must be retained for a longer period, however, if required by the applicable regulatory requirements or if needed by GW.

GW will inform the investigators for each trial site in writing of the need for record retention. No trial document may be destroyed without prior written agreement between GW and the investigator. Should the investigator wish to assign the trial records to another party or move them to another location, he/she must notify GW in writing of the new responsible person and/or the new location.

### **16.3 Trial Monitoring and Data Collection**

The GW representative and regulatory authority inspectors are responsible for contacting and visiting the investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial, e.g., eCRFs and other pertinent data, provided that patient confidentiality is respected.

The GW trial monitor, or designee, is responsible for inspecting (onsite or remotely) the eCRFs and available electronic diary data at regular intervals throughout the trial to verify adherence to the protocol, completeness, accuracy, and consistency of the data and adherence to local regulations on the conduct of clinical research. The trial monitor must have access to patient medical records and other trial-related records needed to verify the entries on the eCRFs.

The investigator agrees to cooperate with the trial monitor to ensure that any problems detected in the course of these monitoring visits are resolved.

To ensure the quality of clinical data across all patients and sites, a clinical data management review will be performed on patient data received at GW or a contract research organization (CRO). During this review, patient data will be checked for consistency, omissions, and any apparent discrepancies. In addition, the data will be reviewed for adherence to the protocol

and FDA regulations, ICH Tripartite Guideline for GCP Topic E6(R2), and all other applicable regulatory requirements. To resolve any questions arising from the clinical data management review process, data queries and/or site notifications will be sent to the trial site for completion and then returned to GW or the CRO, as applicable.

#### **16.4 Quality Assurance**

In accordance with the FDA regulations, EU Clinical Trials Directive/ICH Tripartite Guideline for GCP Topic E6(R2), and the sponsor's audit plans, representatives from GW's Clinical Quality Assurance Department may select this trial for audit. Inspection of site facilities (e.g., pharmacy, drug storage areas, and laboratories) and review of trial-related records will occur to evaluate the trial conduct and compliance with the protocol, the EU Clinical Trials Directive/ICH Tripartite Guideline for GCP Topic E6(R2), and applicable regulatory requirements.

#### **16.5 Compensation**

GW will indemnify the investigator and the trial site in the event of any claim in respect of personal injury arising due to a patient's involvement in the trial providing that the trial protocol has been adhered to. This would include claims arising out of or relating to the administration of the IMP or any clinical intervention or procedure provided for or required by the protocol to which the clinical trial patient would not otherwise have been exposed, providing there is no evidence of negligence on behalf of the investigator or their team. GW will not be liable for any claims arising from negligence on the part of the investigator or their team.

#### **16.6 Publication Policy**

GW recognizes that there is a responsibility under the regulatory guidelines to ensure that results of scientific interest arising from this clinical trial are appropriately published and disseminated. They will coordinate this dissemination and may solicit input and assistance from the chief/PIs. A summary of the results of this trial will be made available on <http://www.clinicaltrials.gov> and <http://www.clinicaltrialsregister.eu/> (as applicable), as required by US and EU laws, respectively.

Any publication of the trial data will be made in accordance with the terms of the Clinical Trial Agreement.

All publications, e.g., manuscripts, abstracts, oral/slide presentations, or book chapters, based on this trial must be submitted to the GW Medical Writing Department and, as applicable, GW Publication Committee for corporate review before release. To ensure adequate time for GW to make comments and suggestions where pertinent, all such material should be submitted to them at least 60 days prior to the date for submission for publication, public

dissemination, or review by a publication committee. The PIs must then incorporate all reasonable comments made by GW into the publication.

GW also reserves the right to delay the submission of such information by a period of up to 6 months from the date of first submission to them in order to allow them to take steps to protect proprietary information where applicable.

### **16.7 Intellectual Property Rights**

All intellectual property rights owned by or licensed to either GW or the PIs, other than those arising from the clinical trial, will remain their property. All intellectual property rights arising out of the clinical trial will vest in or be exclusively licensed to GW and, as such, the PI must promptly disclose all knowledge to GW and refrain from using such knowledge without the prior written consent of GW.

### **16.8 Confidential Information**

GW and the PI must ensure that only personnel directly concerned with the trial are party to confidential information and that any information coming to either party about the other during the course of the trial must be kept strictly confidential and must not be disclosed to any third party or made use of without the prior written consent of the other.

## **17 REFERENCES**

- <sup>1</sup> Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. *Autoimmun Rev.* 2012;11:167-73.
- <sup>2</sup> Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. *Handb Clin Neurol.* 2014;122:15-58.
- <sup>3</sup> Browne P, Chandraratna D, Angood C, et al. *Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.* *Neurology* 2014;83:1022-4.
- <sup>4</sup> Zettl UK, Henze T, Essner U, Flachenecker P. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move 1). *Eur J Health Econ.* 2013;15:953-66.
- <sup>5</sup> Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. *Acta Neurol Scand.* 2014;129:13-20.
- <sup>6</sup> Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmet TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. *Mult Scler.* 2004;10:589-95.
- <sup>7</sup> Goldenberg MM. Multiple sclerosis review. *P T.* 2012;37:175-84.
- <sup>8</sup> Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. *Neurorehabil Neural Repair.* 2003;17:66-70.
- <sup>9</sup> Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. *Health Technology Assessment.* 2003;7:1-111.
- <sup>10</sup> Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis clinical characteristics, treatment and quality of life. *Act Neurol Scand.* 2004;129:154-62.
- <sup>11</sup> Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. *Int J Neurosci.* 2013;123:850-8.
- <sup>12</sup> Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. *Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.* *Eur Neurol.* 2006;56:78-105.
- <sup>13</sup> Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. *Int J MS Case.* 2013;15:146-58.
- <sup>14</sup> Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. *Expert Rev Pharmacoecon Outcomes Res.* 2011;11:205-13.
- <sup>15</sup> Investigator's Brochure: Sativex Oromucosal Spray. GW Pharma Ltd. Edition 22.1 and Addendum 1, January 2020.
- <sup>16</sup> Leocani L, Nuara A, Houdayer E, et al. Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. *J Neurol.* 2015;262(11):2520-7.
- <sup>17</sup> Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. *NeuroRehabilitation.* 2008;23:231-7.

## Appendix 1 SCHEDULE OF ASSESSMENTS

Period	Screening		Treatment Period 1				Treatment Period 2				Safety Follow-up
	Visit 1	Visit 2	Visit 3 (Phone C all)	Visit 4	Visit 5 <sup>a</sup>	Visit 6	Visit 7 (Phone Call)	Visit 8	Visit 9		
Day/Hour	Days-28 to -1	Day 1 predose	Day 1 2-4 hrs postdose	Day 8 (±1 day)	Day 15 (±1 day)	Day 21 (±2 days)	Day 31 predose (±1 day)	Day 31 2-4 hrs postdose	Day 38 (±1 day)	Day 45 (±1 day)	Day 51 (±2 days) End of Treatment Visit
Informed consent	X										Day 58 (+ 3 days)
Eligibility check	X	X									
Demographics	X										
Previous cannabis use	X										
Medical history	X										
Electronic diary training	X										
Randomization		X									
Concomitant medications											Assessed at each visit
AEs											Assessed at each visit
Physical examination <sup>b</sup>	X					X					X
Examination of oral mucosa	X	X			X	X	X			X	X
Body weight measurement	X	X					X				X
Vital signs	X	X	X		X	X	X			X	X
12-lead ECG	X					X					X

Period	Screening		Treatment Period 1				Treatment Period 2			Safety Follow-up
	Visit Number	Visit 1	Visit 2	Visit 3 (Phone C all)	Visit 4	Visit 5 <sup>a</sup>	Visit 6	Visit 7 (Phone Call)	Visit 8	
Day/Hour	Day -28 to -1	Day 1 predose	Day 1 2-4 hrs postdose	Day 8 ( $\pm 1$ day)	Day 15 ( $\pm 1$ day)	Day 21 ( $\pm 2$ days)	Day 31 predose ( $\pm 1$ day)	Day 38 ( $\pm 1$ day)	Day 45 ( $\pm 1$ day)	Day 51 ( $\pm 2$ days) End of Treatment Visit
Clinical laboratory blood sampling (hematology and biochemistry)	X									
Dipstick urinalysis	X					X				
Urine drug screen (including THC)	X	X								
Serum/urine pregnancy test (if appropriate) <sup>c</sup>	X	X					X			
Blood THC test	X									
PK blood sampling (IMP) <sup>d</sup>		X	X			X	X	X	X	
11-Point NRS spasticity <sup>e</sup>	X	X				X	X			
Daily spasm count <sup>e</sup>	X	X				X	X			
Use of antispasticity medications <sup>e</sup>	X	X				X	X			
IMP dosing record <sup>e</sup>		X				X	X			

**SPONSOR: GW PHARMA LIMITED**

Study Code: GWSP20105  
 EudraCT Number: 2020-003271-18  
 GWSP20105 Protocol V1 22Jul2020

Period	Screening		Treatment Period 1				Treatment Period 2			Safety Follow-up
	Visit Number	Visit 1	Visit 2	Visit 3 (Phone C all)	Visit 4	Visit 5 <sup>a</sup>	Visit 6	Visit 7 (Phone Call)	Visit 8	
Day/Hour	Day -28 to -1	Day 1 predose	Day 1 2-4 hrs postdose	Day 8 ( $\pm 1$ day)	Day 15 ( $\pm 1$ day)	Day 21 ( $\pm 2$ days)	Day 31 predose ( $\pm 1$ day)	Day 38 ( $\pm 1$ day)	Day 45 ( $\pm 1$ day)	Day 51 ( $\pm 2$ days) End of Treatment Visit
MAS <sup>f</sup>	X	X	X			X	X			Day 58 (+3 days)
MSSS-88						X				X
T25FW test <sup>g</sup>		X				X	X			X
C-SSRS	X	X			X	X	X			X
IMP dosing training		X								
IMP dosing <sup>h</sup>		X				X	X			X
IMP dispensing <sup>i</sup>		X			X		X		X	
IMP collection and compliance review				X	X	X			X	

AE = adverse events; C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; EoT = end of treatment; IMP = investigational medicinal product; MAS = Modified Ashworth Scale; MS = multiple sclerosis; MSSS-88 = Multiple Sclerosis Spasticity Scale; NRS = Numerical Rating Scale; PK = pharmacokinetics; T25FW = Timed 25-Foot Walk; THC =  $\Delta^9$ -tetrahydrocannabinol.

<sup>a</sup> A washout period of at least 7 days will separate the 2 treatment periods. Following the final dose of IMP in Treatment Period 1, in the morning of Visit 5 (Day 21), patients will discontinue treatment with IMP for the 7 days prior to Visit 6 (Day 31). During the washout period, patients will continue to take their current MS antispasticity medications without any changes in dose.

<sup>b</sup> A comprehensive physical examination, including an assessment of height, will be completed at Screening (Visit 1) only; subsequent physical examinations will be symptom-directed.

<sup>c</sup> Serum pregnancy test at Visits 1 and 10; urine pregnancy test at Visits 2 and 6 (predose).

<sup>d</sup> On the day before PK blood sampling at Visits 4, 5, 8, and 9, patients will be prompted to record whether they started their morning and evening doses of IMP within 30 minutes of a snack or meal. On the day of PK blood sampling, the exact time and date of PK blood sampling and the time of the patient's snacks and meals should be recorded. See Section 9.2.12.1 for the PK blood sampling schedule. Please note that more than one PK sample may be collected at distinct time points during a single visit.

**SPONSOR: GW PHARMA LIMITED**

Study Code: GWSP20105  
EudraCT Number: 2020-003271-18  
GWSP20105 Protocol V1 22Jul2020

<sup>e</sup> Patients will record their 11-point NRS spasticity score, spasm count, and use of antispasticity medications in an electronic diary once daily, around the same time each day, preferably in the evening before retiring to sleep, for at least 7 days prior to Visits 2 and 6 and throughout the trial until Visit 9. Investigational medicinal product dosing will be recorded by the patient in an electronic diary from Visits 2 through 9.

<sup>f</sup> MAS assessments will occur at Visit 1 (Screening) and at scheduled time points before (Visits 2 and 6 [predose]) and after (Visits 2, 5, 6, and 9 [3 hours  $\pm$ 15 minutes postdose]) IMP administration; for Visits in which the morning dose consists of more than 1 spray (Visits 5 and 9), postdose assessments will occur 3 hours  $\pm$ 15 minutes after the first spray of the morning dose.

<sup>g</sup> Non-ambulatory patients are not expected to perform the T25FW test.

<sup>h</sup> IMP administration of the morning dose will occur at the trial site within 30 minutes after a standardized snack containing at least 300 kcal (of which approximately 30 kcal is composed of fat) under the supervision of site staff. On the days of scheduled MAS assessments other than Visit 1, patients who are taking antispasticity therapy should take their regular morning dose at least 1 hour before administration of IMP; IMP will not be administered in the evening of Days 21 and 51.

<sup>i</sup> In cases where patients are not able to attend study visits due to special circumstances (e.g., COVID-19 pandemic), the investigator will discuss with the Sponsor potential mitigation approaches for IMP dispensing, secure delivery, and collection.

## **Appendix 2 TRIAL PERSONNEL**

### **Appendix 2.1 Investigator Details**

At the time of protocol production, the participating investigators have not been confirmed. A list of all investigators will be maintained within the GW master files (electronically and added to the trial master file at the end of the trial).

### **Appendix 2.2 Sponsor Contact Details**

Pharmacovigilance Department	<b>Email:</b> <a href="mailto:pvd@gwpharm.com">pvd@gwpharm.com</a> <b>Fax:</b> +44 (0)1223 233 319 <b>USA Toll-free Fax:</b> +1-866-234-1751 <b>Tel:</b> +44 (0)1223 233 410
Sponsor:	GW Pharma Ltd Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ United Kingdom Tel: +44 (0) 1223 266 800 Fax: +44 (0) 1223 235 667
Medical Advisor & Clinical Project Manager:	Please refer to the Sponsor and Related Contact Details form in the trial site file.
Clinical Trial Supplies:	GW Pharma Ltd Tel: +44 (0) 1795 435 029 Fax: +44 (0) 1795 475 439

### **Appendix 2.3 Contract Research Organizations**

At the time of protocol production, the contract research organizations, and the central and bioanalytical laboratories for the trial had not been confirmed. A corresponding list will be maintained within the GW master files (electronically and added to the trial master file at the end of the trial).

## **Appendix 3      QUESTIONNAIRES/ASSESSMENTS**

At the time of protocol finalization, questionnaire/assessment licensing has not yet been obtained. Copies of the questionnaires/assessments will be made available to all investigators.

## **Appendix 4      PROHIBITED MEDICATIONS SOLELY METABOLIZED BY UGT1A9 AND UGT2B7**

Examples of medications that are solely metabolized by UGT1A9 and UGT2B7 and prohibited for the duration of the trial are provided in the sections below.

### **Appendix 4.1      Prohibited Medications Metabolized Solely by UGT1A9**

- Flavopiridol
- Propofol

### **Appendix 4.2      Prohibited Medications Metabolized Solely by UGT2B7**

- Benoxaprofen
- Carbamazepine
- Codeine
- Cyclosporin A
- Epirubicin
- Indomethacin
- Tacrolimus
- Tiaprofenic acid
- Zaltoprofen
- Zomepirac
- Zidovudine